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In 2011, two highly related hexanucleotide repeat expansions (HRE) were discovered as 
the causes of two different diseases – an intronic G4C2 HRE in the C9ORF72 gene locus 
represents the most prevalent genetic cause of Amyotrophic Lateral Sclerosis (ALS) and 
Frontotemporal Dementia (FTD), referred to as c9FTD/ALS, and a TG3C2 HRE in the first 
intron of NOP56 gene was independently identified as the genetic cause for a clinically 
disparate disease, Spinocerebellar Ataxia type 36 (SCA36).  The overall aim of this 
proposal is to elucidate the molecular mechanisms by which hexanucleotide repeat 
expansions result in neurodegenerative disease, and to identify which mechanisms are 
responsible for the disease-specific pattern of neuronal degeneration and loss in these 
disorders.  Aim (1) will determine whether these intronic hexanucleotide repeats are 
unconventionally translated into dipeptide repeats, Aim (2) will identify and compare 
disease specific RNA-protein interactions, and lastly we will use next generation 
sequencing to elucidate shared and distinct dysregulated pathways in these two disorders. 
We hypothesize that a comprehensive and comparative analysis using c9FTD/ALS and 
SCA36 patient samples will provide us with a unique opportunity to gain a thorough 
understanding of the common and disease-specific pathomechanisms of these devastating 









All self-replicating, cellular organisms contain deoxyribonucleic acid (DNA).  From 
archaea to humans, the storage and transfer of genetic information relies on various 
combinations of the four same DNA nucleotides: adenine (A), cytosine (C), guanine (G), 
and thymine (T).  In the genomes of all organisms, specific combinations of nucleotides 
are used as a template to produce the workhorses of the cell – proteins.  However, a large 
portion of the genome, particularly in humans, is made up of stretches of nucleotides that 
are highly repetitive and do not encode for proteins.  Once thought to be “junk DNA”, these 
sequences are now known to play an important role in human health and disease.  This 
thesis is focused on understanding how neurological disorders arise when the integrity of 
these sequences is compromised.       
1.1 Repeat Expansion Disorders 
Pathological expansions of short, genomic repeat sequences, referred to as 
microsatellite expansions, have been implicated in a number of neurodevelopmental, 
neurodegenerative, or neuromuscular disorders (Pearson et al., 2005).  These pathological 
expansions can be found in both translated (exons) or untranslated (5’ UTR, 3’ UTR, 
introns) regions of a gene (DeJesus-Hernandez et al., 2011; Ross and Tabrizi, 2011; Udd 
and Krahe, 2012) (Fig 1.1).  The first repeat expansion, an expanded CGG repeat in the 
“The very large number of members in the families of 
repeated sequences remains a most surprising feature for 
which an explanation must be sought.  It may be 
reasonably predicted the large-scale new patterns of 
relationship among proteins await discovery” 
  R.J. Britten & D.E. Kohne, Science, 1968 
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FMR1 gene, was discovered in 1991 by researchers at Emory University (Verkerk et al., 
1991).  Since, repeat expansions have been implicated in neurological disorders spanning 
the clinical spectrum including myotonic dystrophy, ALS/FTD, Huntington’s disease and 
the hereditary ataxias(Paulson, 2018) (Table 1.1).  The molecular mechanisms underlying 
disease in microsatellite expansions are varied and can result from either loss-of-function 
or gain-of-function mechanisms.  These expanded repeats are typically unstable and can 
grow in repeat size across generations which in turn can modify the toxicity or the 
underlying mechanism associated with a particular repeat expansion.  The focus of this 




Figure 1.1: Microsatellite expansion mutations.   Schematic illustrating the repeat 






Table 1.1:  Neurological disorders caused by repeat expansions 
Disease Repeat Gene Location Repeat Size† Reference 
Fragile X Syndrome (FXS) CGG FMR1 5’ UTR > 200 (Verkerk et al., 1991) 
Spinal Bulbar Muscular Atrophy 
(SBMA) CAG AR Exon 38 – 62 (Spada et al., 1991) 
Spinocerebellar Ataxia Type 1 
(SCA1) CAG ATXN1 Exon 40 – 81 (Orr et al., 1993) 
Spinocerebellar Ataxia Type 2 
(SCA2) CAG ATXN2 Exon 32 – 79 (Pulst et al., 1996) 
Spinocerebellar Ataxia Type 3 
(SCA3) CAG ATXN3 Exon 52 – 86 (Kawaguchi et al., 1994) 
Spinocerebellar Ataxia Type 6 
(SCA6) CAG CCNA1A Exon 19 – 33 (Zhuchenko et al., 1997) 
Spinocerebellar Ataxia Type 7 
(SCA7) CAG ATXN7 Exon 38 – 130 (David et al., 1997) 
Spinocerebellar Ataxia Type 8 
(SCA8) CAG ATXN8 3’ UTR 71 – 1,300 (Koob et al., 1999) 
Spinocerebellar Ataxia Type 10 
(SCA10) ATTCT ATXN10 Intron 400 – 4,500 (Matsuura et al., 2000) 
Spinocerebellar Ataxia Type 12 
(SCA12) CAG PPP2R2B 5’ UTR 51 – 78 (Fujigasaki et al., 2001) 
Spinocerebellar Ataxia Type 17 
(SCA17) CAG TBP Exon 44 – 67 (Koide et al., 1999) 
Fragile X Tremor/Ataxia 
Syndrome (FXTAS) CGG FMR1 5’ UTR 55 – 200 (Hagerman et al., 2001) 
Huntington’s Disease (HD) CAG HTT Exon > 37 (MacDonald et al., 1993) 
Myotonic Dystrophy Type 1 
(DM1) CUG DMPK 3’ UTR 50 – 1,000 (Brook et al., 1992) 
Myotonic Dystrophy Type 2 
(DM2) CCTG CNBP 3’ UTR 75 – 11,000 (Liquori et al., 2001) 
Spinocerebellar Ataxia Type 31 
(SCA31) TGGAA BEAN Exon 
>2.5kb insertion 
length* (Sato et al., 2009) 
Spinocerebellar Ataxia Type 36 
(SCA36) GGCCTG NOP56 Intron 650 – 2,500 (Kobayashi et al., 2011) 
C9orf72-Amyotrophic Lateral 
Sclerosis / Frontotemporal 
Dementia (c9ALS/FTD) 
GGGGCC C9orf72 Intron 700 – 4,400 (DeJesus-Hernandez et al., 2011; Renton et al., 2011) 
Neuronal Intranuclear Inclusion 
Disease (NIID) GGC NOTCH2NLC 5’ UTR 66 – 517 
(Sone et al., 2019; Tian et 
al.) 
†Repeat size refers to number of repeats found in affected patients 
*The SCA31 associated expansion is typically a complex repeat.  Instead of number of repeats, usually the insertion size is referred to. 
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1.2 Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disorder with a 
fatal prognosis.  Characterized by the loss of neurons that are involved in voluntary muscle 
control, ALS renders those afflicted paralyzed and ultimately unable to breathe (Brown 
and Al-Chalabi, 2017).  While tremendous efforts have been made to combat this 
devastating disease, biological insights into the disorder have only further added to its 
mystery and therapies to extend or improve quality of life are limited. 
1.2.1 Historical Insights 
In the early 19th century, Sir Charles Bell, who is most often associated with the 
eponymous “Bell’s Palsy” disorder, published a seminal text describing the human nervous 
system (Bell, 1824).  A key concept advocated by Bell was the anatomical and functional 
distinction between sensory and motor nerves.  Bell is credited with making the first 
recorded report of amyotrophic lateral sclerosis (ALS) in which he refers to a patient, ‘Mrs. 
G’., whose case (No. XLVIIl; Case 47) is “very interesting, and might have been used as 
illustrative of my [Bell’s] views of the nerves” (Bell, 1830).  At the time, the patient was in 
the sixth decade of her life and bed-ridden.   She was described as having a progressive 
weakening of her extremities with “twitching of the muscles.”   Additionally, her “speech 
became more and more indistinct” (dysarthria) and her “difficulty swallowing gradually 
increased” (dysphagia).  Notably, however, throughout the course of her disease, she never 
experienced any loss of sensation and the “slightest pressure of the legs, toes, fingers, or 
arms, was immediately perceived.”    At autopsy her physician and a former pupil of Bell’s, 
Thomas Ingel, made a keen observation that the anterior part of the spinal cord was in a 
 5 
“semifluid state, approaching nearly to the consistence of cream”, however the posterior 
part of the spinal cord remained firm.  Following Bell’s initial description of a progressive 
neurological disorder affecting only the motor system, a number of prominent neurologists 
at the time began to present similar case reports including Guillaume-Benjamin Duchenne 
(Duchenne, 1847), François-Amilcar Aran (Aran, 1850), Jean Cruveilhier (Cruveilhier, 
1853), and Jacob Lockhart Clarke (Radcliffe and Clarke, 1862).  However, it was not until 
keen observations made by Jean-Martin Charcot that amyotrophic lateral sclerosis as a 
distinct clinical disorder was fully realized.  Charcot’s definition of ALS developed over a 
number of years and resulted from a number of cases that allowed him to correlate clinical 
symptoms seen in ALS patients and neuropathological findings.  In 1865, Charcot 
presented a case of a women who had presented with considerable weakness in her 
extremities in addition to what was termed at the time “contractures” (spasticity).  Charcot 
observed that, at autopsy, there were “sclerotic changes” and that the “lateral columns have 
in their most superficial and posterior regions, a gray, semitransparent appearance” 
(Charcot, 1865; Goetz, 2000).  A few years later, Charcot had observed that individuals 
who had pediatric forms of progressive muscular atrophy had considerable degeneration 
of the anterior horn cells (Charcot, 1869).  These two studies allowed Charcot to relate the 
sclerotic changes in the lateral columns to the clinical finding of “contractures” and 
degeneration of the anterior horn cells to muscular atrophy.  Subsequent encounters with 
patients presenting with both contractures and muscular atrophy formed the basis for his 
first diagnosis of ALS.  Charcot’s naming of this disorder, amyotrophic lateral sclerosis 
perfectly captured the clinico-anatomical findings: a (without) + myo (muscle) + trophy 
(support) referring to the degeneration of the anterior horn and lateral sclerosis capturing 
the loss of the lateral columns (i.e. axonal tracts of the upper motor neurons).  While 
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Charcot was able to systematically and wholly relate clinical symptoms with 
neuropathological findings, it should be noted that both Cruveilhier and Lockhart-Clark 
had noted in their seminal texts that anterior horn cells of the spinal cord were lost in 
patients. 
1.2.2 The Genetics of ALS 
During the 19th century, morbid pathology (i.e. clinico-pathological correlations) 
provided unprecedented insight into diseases of the nervous system.  However, it wasn’t 
until the mid to late 20th century that our understanding of the genetic code, 
conceptualization of mathematical principles to model population genetics, and the 
development of tools to analyze genetic sequences allowed for a new scientific revolution 
to emerge in neurology. 
The prevailing thought at the time was that motor neuron disease was an isolated and non-
hereditary disorder, with even Charcot claiming that it was never familial (Charcot, 1869). 
However, the notion that the same disease could afflict other members of a family was 
noted as early as 1850 when Aran commented that his patient suffering from progressive 
muscular atrophy had three relatives –  a sister and two maternal uncles –  who experienced 
similar symptoms before succumbing to the disease (Aran, 1850; Siddique and Ajroud-
Driss, 2011).  In the first edition of his text on diseases of the nervous system, the famed 
US surgeon general William Alexander Hammond comments “hereditary influence is a 
well-recognized predisposing cause,” and offers as an example two cases sent to him that 
were brothers as well as nine other patients under his care who had relatives afflicted by 
the same disease (Hammond, 1871).  In a later edition he provides additional evidence for 
a hereditary link to progressive muscular atrophy (Hammond, 1881).  He shares an 
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interesting case that was made known to him by Dr. R.F. Andrews of Gardner, 
Massachusetts in 1874,  concerning a patient first seen at Massachusetts General Hospital 
in 1872.    In addition to comments about the case from Dr. Andrews, there was a pamphlet 
entitled “Muscular Atrophy” written by the patient himself, E. Wetherbee, describing the 
remarkable history of what progressive muscular atrophy in his family for several 
generations.  According to E. Wetherbee, this hereditary disorder his family suffered from 
was known as the “Weatherbee Ail” by their family and friends.  Other accounts of familial 
forms of the disease were also communicated by a number of neurologists.  Another 
remarkable example of familial progressive muscular atrophy is the Bessel family seen by 
Dr. Bernhard Naunyn in Germany; over six generations of family members had suffered 
from this disease (Naunyn, 1873).  In 1880, William Osler of McGill University in Canada 
published an article in which he presented a “genealogical chart” of the Farr family and 
stated it “illustrates well the hereditary nature of progressive muscular atrophy” (Osler, 
1880).  A member of the Farr family had recently been seen by Dr. Osler and diagnosed 
with progressive muscular atrophy.  Intriguingly, the patient indicated that 13 family 
members across two generations “have been affected by this disease.”  Unbeknownst at the 
time, the Farr family’s role in elucidating the etiology of familial progressive muscular 
atrophy was much more far-reaching than simply an early account of the hereditary nature 
of progressive muscular atrophy.   
Although these early reports of familial progressive muscular atrophy/ALS 
provided reasonable evidence of its hereditary nature, it remained widely believed that ALS 
was not an inherited disorder.  However, an article published in 1955 argued that “18 
extensive pedigrees compatible with dominant inheritance;” had been described in the 
literature furthermore, the authors presented six new pedigrees that demonstrated ALS can 
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be hereditary (Kurland and Mulder, 1955).  Subsequent studies and reviews of reported 
familial cases suggested that 5-10% of ALS cases are familial (Mulder et al., 1986).  As 
our understanding and ability to analyze genomic sequences advanced, investigators began 
to search for genetic aberrations that may give rise to familial forms of ALS.  Using genetic 
linkage analysis, Siddique and colleagues were able to identify a genetic locus on 
chromosome 21 that was strongly associated with a number of pedigrees of familial ALS 
(fALS)  (Siddique et al., 1991; Siddique et al., 1989).  In 1993, mutations in the Cu/Zn 
superoxide dismutase 1 gene (SOD1) within the linked region of chromosome 21 were 
identified as the first genetic cause of fALS (Rosen et al., 1993).  This discovery prompted 
others to search for candidate ALS genes in both familial and sporadic ALS.  In the early 
2000’s genetic based efforts  as well as insights from neuropathological findings began to 
pay off as a number of genetic mutations were implicated in ALS (Kabashi et al., 2008; 
Kwiatkowski et al., 2009; Neumann et al., 2006; Sreedharan et al., 2008).  The discovery 
that TDP-43 was the main component of ubiquitinated inclusions found in the majority of 
ALS as well as FTLD-U cases supported a long suspected idea that ALS and FTD are part 
of a disease continuum (Ferrari et al., 2011; Lillo and Hodges, 2009; Neumann et al., 2006). 
Concomitantly, genetic linkage studies in a number of large families with individuals 
suffering from ALS, and FTD identified a region on chromosome 9 as a new ALS-FTD 
locus (Morita et al., 2006; Valdmanis et al., 2007; Vance et al., 2006).  These findings set 
off a hunt to discover the chromosome 9 linked mutation(Gijselinck et al., 2010; Le Ber et 
al., 2009; Luty et al., 2008; Pearson et al., 2011).  In 2011, these efforts culminated in the 
discovery by two independent groups that the causal mutation was a massively expanded 
G4C2 repeat in the intron of C9orf72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011).  
The discovery of the C9orf72-linked mutation was unique because it was the first repeat 
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expansion implicated in ALS and FTD.  Furthermore, the frequency of the C9orf72-linked 
mutation was remarkable as follow up studies estimated this genetic mutation accounted 
for ~40% of familial ALS cases and ~10% of sporadic ALS cases worldwide (Majounie et 
al., 2012).   Since the initial discovery of the SOD1 mutation, a staggering number of 
genetic variants have been linked to ALS, however only a subset of these are believed to 
be truly causal (Brown and Al-Chalabi, 2017; Taylor et al., 2016).  Advances in next 
generation sequencing technologies and concerted worldwide efforts to discover new ALS 
genes will undoubtedly expand our understanding of ALS.  It bears mentioning that an 
example of these efforts is the multinational collaboration, Project MinE 
(www.projectmine.com) which aims to whole genome sequence 15,000 ALS patients.  
While only a fraction of genomes have been sequenced to date, a number of new ALS 
variants have been identified including variants in NEK1, KIF5A, and C21orf2 (Kenna et 
al., 2016; Nicolas et al., 2018).  
1.3 C9orf72-linked ALS/FTD 
The discovery that a G4C2 repeat expansion in the first intron of C9orf72 is the most 
common genetic cause of ALS and FTD was a major breakthrough in our understanding 
of these neurological disorders.   
1.3.1 The C9orf72 Gene and Protein 
Prior to the discovery of the G4C2 repeat expansion, the C9orf72 gene was only a 
predicted gene structure in the human genome.  Once it was reported to be causal for 
ALS/FTD, a number of studies began to elucidate its function.  Somewhat serendipitously, 
an early study using bioinformatic methods to discover novel proteins containing the 
tripartite DENN module, identified the C9orf72 protein as a candidate DENN type GDP-
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GTP exchange factor (GEF) (Levine et al., 2013; Zhang et al., 2012).  DENN (differentially 
expressed in normal and neoplastic cells) type proteins are evolutionary conserved proteins 
that interact with Rab GTPases and are thought to function as Rab GEFs (Marat et al., 
2011).  This initial report identifying the C9orf72 protein as a Rab-GEF suggested that it 
plays a role in Rab-dependent vesicular trafficking.  Follow up biochemical studies 
demonstrated that the C9orf72 protein co-localizes with Rab 1, Rab 5, Rab 7, and Rab 11 
and provided evidence that the C9orf72 was involved in the regulation of endocytosis and 
autophagy (Farg et al., 2014).  C9orf72 protein was shown to be necessary for the formation 
of the autophagosome and reduction in C9orf72 resulted in impaired autophagy leading to 
the accumulation of cytoplasmic p62 aggregates (Sellier et al., 2016; Webster et al., 2016).  
Recent studies have suggested that the C9orf72 protein forms a tripartite complex with 
WDR41 and SMRC8 (Amick et al., 2016; Sellier et al., 2016; Sullivan et al., 2016; Yang 
et al., 2016); interestingly, the SMRC8 protein was also predicted to be a DENN type 
protein (Zhang et al., 2012) and has been implicated previously in autophagy.  Collectively 
these studies have demonstrated that the C9orf72 protein is likely involved in the 
autolysosomal pathway. 
1.3.2 Disease Mechanism 
A number of mechanisms have been proposed for ways in which an expanded 
microsatellite repeat can elicit toxicity.  Similar to other repeat expansions, a number of 
putative disease mechanisms have been proposed for c9ALS/FTD including 
haploinsufficiency of the C9orf72, RNA mediated toxicity resulting from G4C2 repeat 
containing RNA, and translation of the G4C2 repeat to produce aberrant dipeptide repeats 
(Fig 1.2).    
 11 
Intranuclear inclusions of repeat containing RNA (“RNA foci”) is a hallmark of 
c9ALS/FTD.  A leading hypothesis is that these foci sequester a number of RNA binding 
proteins (RBPs), thereby reducing the functional pool of these RBPs.  Since their discovery 
in c9ALS/FTD tissue, a number of studies have sought to determine which RNA binding 
proteins are sequestered by these RNA foci.  A number of RBPs have been identified 
including Pur-alpha , ADARB2 (Donnelly et al., 2013b), ALYREF (Cooper-Knock et al., 
2014), various HNRNPs (Conlon et al., 2016; Cooper-Knock et al., 2014; Mori et al., 
2013a), and nucleolin (Haeusler et al., 2014a).  Furthermore, bidirectional transcription of 
the C9orf72 locus results in the formation of antisense transcripts that form RNA foci as 
well and sequester RNA binding proteins (Cooper-Knock et al., 2015).  The downstream 
molecular consequences of RBP sequestration have only begun to be examined, but recent 
studies have demonstrated that wide spread changes in alternative splicing events result 
from RBP sequestration (Conlon et al., 2016; Prudencio et al., 2015). 
Shortly after the discovery of the C9orf72 mutation, it was found that C9orf72 repeat 
containing RNA could undergo a non-canonical form of translation, termed repeat-
associated non-AUG (RAN) translation resulting in the production of repeating dipeptide 
species (Mori et al., 2013b).  Intriguingly, RAN translation can occur in both the sense and 
antisense direction to produce five distinct DPR species.  Since their initial report, a number 
of studies have investigated the toxicities of individual DPRs.  The arginine-rich DPRs, 
poly(GR) and poly(PR)  have consistently been demonstrated to be toxic in vitro and in 
vivo  and a number of different mechanisms by which they elicit toxicity have been 
proposed including impairment of protein translation and ribosomal biogenesis  (Choi et 




Figure 1.2: Putative Disease Mechanisms in c9ALS/FTD. 
Putative disease mechanisms in c9ALS/FTD include 1) haploinsuffiency of the NOP56 
gene, 2) RNA-mediated toxicity via sequestration of RNA binding proteins, and 3) 
production of aberrant dipeptide repeats.  Adapted from (Gitler and Tsuiji, 2016). 
 
 
1.3.3 Neuropathology of c9ALS/FTD 
A number of neuropathological findings are shared between c9ALS/FTD and other 
forms of ALS and FTD.  TDP-43 pathology, i.e. the nuclear clearing, cleavage and 
phosphorylation of TDP-43, found in most cases of ALS and common subtypes of FTD, is 
a neuropathological hallmark of c9ALS/FTD as well.  Early studies found that a unique 
neuropathological finding specific to c9ALS/FTD was the presence of neuronal 
cytoplasmic inclusions (NCI) and neuronal intranuclear inclusions (NII) that are negative 
for TDP-43, but immunoreactive for ubiquitin and p62, both markers of the ubiquitin 
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proteasome system (Al-Sarraj et al., 2011; Mackenzie and Neumann, 2016).  Subsequent 
investigations demonstrated that these TDP-43 negative, p62/ubiquitin positive inclusions 
were in fact aberrant dipeptide repeats (DPR) produced by unconventional translation of 
the G4C2 repeat (Ash et al., 2013; Gendron et al., 2013; Mori et al., 2013b; Zu et al., 2013).  
Interestingly, the G4C2 repeat in C9orf72 can be translated in all six reading frames, both 
sense and antisense, to produce five different dipeptide repeat species: Glycine-Alanine 
(GA), Glycine-Proline (GP), Glycine-Arginine (GR) in the sense direction and Glycine-
Proline (GP), Proline-Alanine (PA), Proline-Arginine (PR) in the antisense direction.  The  
sense DPRs are more prevalent in post-mortem samples than the antisense DPRs, with 
poly(GA) being the most abundant followed by poly(GP) and then poly(GR).  Regionally, 
DPRs are most abundant in neurons of the frontal cortex, hippocampus, and granule layer 
of the cerebellum; interestingly, they are rarely found in the spinal cord (Gomez-Deza et 
al., 2015; Vatsavayai et al., 2019).  In addition to cells containing single DPR inclusions, 
there is evidence that the sense DPRs, poly(GP) and poly(GR) co-localize with poly(GA) 
inclusions.  In fact, poly(GP) inclusions were almost exclusively co-localized with 
poly(GA) in the temporal lobe of three cases (Lee et al., 2017); furthermore, a recent report 
suggests that poly(GA) can sequester poly(GR) into cytoplasmic inclusions (Yang et al., 
2015).  A number of studies have reported other proteinaceous inclusions that colocalize 
with poly(GA) including Unc119 (May et al., 2014), Drosha (Porta et al., 2015), and 
HR23B (Zhang et al., 2016) while poly(GR) has been shown to co-localize with a number 
of ribosomal proteins including S6, L21, and eIF3h in the frontal cortex of three patients 
(Zhang et al., 2018).   
1.3.4 Mouse models of c9ALS/FTD 
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.  The G4C2 repeat expansion can potentially elicit toxicity through either a loss-of- 
function or gain-of function mechanism, therefore a number of mouse models have been 
generated to study c9ALS/FTD that investigate either C9orf72 haploinsufficiency, RNA 
mediated toxicity or dipeptide repeat toxicity (Table 1.2).  In 2015, the first mouse model 
of c9ALS/FTD was generated by somatic brains transgenesis (SBT) of an adeno-associated 
virus (AAV) encoding 66 G4C2 repeats (Chew et al., 2015).  The AAV-66R mouse model 
recapitulated many cellular phenotypes characteristic of human c9ALS/FTD including the 
formation of RNA foci, the production of DPRs, and the cytoplasmic mislocalization and 
phosphorylation of TDP-43; however, the behavioural and motor phenotypes were mild.  
The authors noted that at 6 months of age, there was observed upper but not lower motor 
neuron loss as well increased anxiety and sociability deficits.  Shortly thereafter, a number 
of groups published C9orf72 BAC transgenic models (Jiang et al., 2016; Liu et al., 2016; 
O'Rourke et al., 2015; Peters et al., 2015).  A BAC transgenic model is hypothetically a 
more disease relevant model since the BAC would contain a large number of G4C2 repeats 
as well as cis-regulatory elements associated with endogenous human C9orf72.   
Surprisingly, although all of the BAC models exhibited characteristic RNA foci and 
dipeptide repeats, behavioural and motor phenotypes were completely absent or mild 
except for the BAC-C9-500 model developed by Liu et al.  This model displayed robust, 
though inconsistent, phenotypes including upper and lower motor neuron loss, neuronal 
cell loss throughout the CNS, hindlimb paralysis, seizures, and even early death.  
Interestingly the BAC-C9-500 model also exhibited robust cytoplasmic TDP-43 
inclusions. The phenotypic discrepancy between this model and the other c9BAC models 
has, understandably, caused consternation in the field.  It should be noted that the BAC-
C9-500 model developed by Liu et al is on a different mouse background compared to the 
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other models.  The c9BAC models in theory allow for analysis of both RNA gain-of-
function toxicity and DPR toxicity; however, it is hard to tease to out which phenotypes 
may or may not be attributed to RNA or DPR toxicity.  Therefore, a number of AAV based 
SBT models have been developed to study the toxicity associated with individual DPRs in 
the absence of toxic RNA.  Similar to the approach employed in the AAV-66R model, 
Zhang et al. used an AAV encoding for poly(GA), poly(GR), or poly(PR) dipeptide repeats 
to assess whether each of these DPRs individually contribute to neurodegeneration (Zhang 
et al., 2018; Zhang et al., 2016; Zhang et al., 2019).  An interesting result from these studies 
suggests that the individual DPRs (i.e. -GA, -GR, or -PR) studied were not sufficient to 
promote TDP-43 pathology.  
Table 1.2: Models of C9orf72-associated ALS/FTD 
Repeat Expansion Models†: 
Model # of G4C2 Repeats Phenotypes
# Pathology Strain Reference 
DPRs pTDP 
AAV-66R 66 
Upper motor neuron loss, 
Increased anxiety, reduced 
motor function 
GA, GP, GR Yes C57BL/6J (Chew et al., 2015) 
AAV-149 149 Motor deficits, astrogliosis, cognitive impairment 
GA, GP, GR, 
PR, PA Yes C57BL/6J (Chew et al., 2019) 
BAC-C9-
500/300 300/500 None GP No SJL/6J (Peters et al., 2015) 
BAC-C9-
(100-100) 100-1000 None GP No C57BL/C3H 




Increased anxiety, spatial 
learning deficits GA, GP, GR No
* C57BL/6J (Jiang et al., 2016) 
BAC-C9-
500 500 
Motor neuron loss, weight loss, 
motor function deficits, seizures, 
clasping, increased anxiety, 
hindlimb paralysis, early death 
GA, GP Yes FVB/NNJ (Liu et al., 2016) 
DPR Models: 







Slight motor deficits as assessed 
by tail-suspension and rotarod, 
astrogliosis, cortical neuron loss 
GA No C57BL/6J (Zhang et al., 2016) 
AAV-GR 100 
Progressive motor deficits, astro- 
& microgliosis in the cortex and 
hippocampus, cortical neuron 
loss.  
GR No C57BL/6J (Zhang et al., 2018) 
AAV-PR 50 
Motor Deficits, neuron loss, 
neuroinflammation, early death. PR No C57BL/6J (Zhang et al., 2019) 
C9orf72 KO Models: 





 Exon 2-6 KO 
Motor deficits (Rotarod), Social 
interaction deficits, reduced 
body weight, splenomegaly, 
lymphadenopathy 
N/A No C57BL/6J (Jiang et al., 2016) 
 Exon 2-6 KO Splenomegaly, lymphadenopathy N/A No C57BL/6J 
(O'Rourke et al., 
2016) 
 Exon 2-6 KO CRISPR-KO  
Reduced body weight, 
splenomegaly, lymphadenopathy N/A No C57BL/6J 
(Burberry et al., 
2016) 
 CRISPR-KO 
Reduced body weight, 
splenomegaly, 
lymphadenopathy, increased in 
autophagy/lysosome markers 
N/A No C57BL/6J (Sullivan et al., 2016) 
 Full KO Reduced body weight, splenomegaly, lymphadenopathy N/A No C57BL/6J 
(Sudria-Lopez et 
al., 2016) 
†See (Batra and Lee, 2017) for detailed review of HRE models  
*Although no pTDP43 inclusions were detected, the authors report increased pTDP in the insoluble fraction as determined by immunoassay 
#Additional phenotype information can be obtained from https://www.alzforum.org/research-models 
‡See (Balendra and Isaacs, 2018) for detailed review of KO models 
 
1.4 Spinocerebellar ataxia (SCA) 
Derived from Greek, the word Ataxia means “without order”(Barboi, 2000).   Ataxia 
is a clinical term that refers to the loss of coordination of voluntary muscle control.  
Although similar symptoms are experienced by patients suffering from ataxia, the etiology 
can differ considerably.  Ataxia can result from genetic or non-genetic origins (Klockgether 
et al., 2019).  Hereditary forms of ataxia can have either an autosomal dominant or 
recessive pattern of inheritance; autosomal dominant ataxias are referred to as the 
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Spinocerebellar Ataxias (SCA).  To date there have been over 49 types of spinocerebellar 
ataxias reported (Pilotto and Saxena, 2018).  The spinocerebellar ataxias are a group of 
progressive degenerative diseases affecting the cerebellum.   Cerebellar ataxia (either 
truncal or appendicular) is a unifying clinical phenotype across all SCAs; however, there 
exists specific clinical symptoms characteristic of a particular SCA type (Shakkottai and 
Fogel, 2013).  Genetic mutations associated with the SCAs can be broadly grouped into 
four groups: the polyglutamine ataxias (e.g. SCA1, SCA2, SCA3), mutations in ion 
channels (e.g. SCA5, SCA6), mutations in signal transduction pathways (e.g. SCA11, 
SCA12), and mutations associated with RNA toxicity (e.g. SCA31, SCA36) (Shakkottai 
and Fogel, 2013); interestingly mutations associated with SCAs in each of these groups 
can result from expansion of microsatellites (Table 1.1).  While, in general the prevalence 
of ataxia is 3 per 100,000 there appears to be a regional and ethnic component to the 
prevalence of a particular SCA type (Pilotto and Saxena, 2018).  The discovery of 
expanded CAG repeats as the genetic cause of SCA1 prompted considerable efforts 
focused on elucidating molecular mechanisms result from CAG expansions.  However, 
research efforts focused on other SCA types have been limited, especially for 
spinocerebellar ataxia type 36.  
1.5 Spinocerebellar ataxia type 36 (SCA36) 
Spinocerebellar ataxia type 36 (SCA36) is a late-onset, progressive 
neurodegenerative disease characterized chiefly by truncal ataxia (Arias et al., 2017).  First 
described clinically by two independent groups, SCA36 was initially referred to as Costa 
da Morte ataxia in the Galician region of Spain and Asidan in the Chugoku region of Japan 
(Arias et al., 2008; Ohta et al., 2007).  Subsequently, it was discovered that both of these 
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ataxic syndromes resulted from a massively expanded GGCCTG repeat in the first intron 
of the gene Nucleolar Protein 56 (NOP56) (García-Murias et al., 2012; Kobayashi et al., 
2011).  SCA36 has since been reported in individuals from Italy, France, China, Taiwan, 
Poland, and the U.S.A. (Lee et al., 2016b; Obayashi et al., 2015; Sarto et al., 2013; Sulek 
et al., 2013; Valera et al., 2017; Zeng et al., 2016).  In addition to truncal ataxia, patients 
present other neurological symptoms to varying extents, including appendicular ataxia, 
sensorineural impairment, and tongue fasciculations and atrophy (Ikeda et al., 2012; Ikeda 
et al., 2013).   
1.5.1 The NOP56 Gene and Protein  
NOP56 encodes for nucleolar protein 56 (NOP56).  NOP56 is a evolutionarily 
conserved 594 amino acid protein involved in ribosomal biogenesis.  More specifically, it 
is a core component of the box C/D small nucleolar ribonucleoprotein (snoRNP) particles.  
NOP56, in conjunction with NOP58, bind the C’/D’ and C/D boxes, respectively of the 
box C/D snoRNP particle, and serves as a scaffold for the 2’-O-methyltransferase, 
Fibrillarin (FBL) (Bizarro et al., 2014).  NOP56 is important for the final maturation of 
activation of box C/D snoRNPs (Lykke-Andersen et al., 2018).   
 
1.5.2 Disease Mechanisms 
While numerous studies have focused on c9ALS/FTD, efforts targets at elucidating 
disease mechanisms in SCA36 have been limited.  Similar to what has been proposed for 
c9ALS/FTD, putative disease mechanisms in SCA36 include haploinsufficiency of the 
NOP56 gene, RNA mediated toxicity resulting from TG3C2 repeat containing RNA, and 
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translation of the TG3C2 repeat to produce aberrant DPRs (Fig 1.3) (Arias et al., 2017).  In 
their initial report describing the SCA36 repeat expansion, Kobayashi et al. demonstrated 
that NOP56 mRNA levels are not affected by the repeat expansion but that miR1292 which 
is located in intron of NOP56 is significantly reduced (Kobayashi et al., 2011).  
Furthermore, using a FISH probe targeting the TG3C2 containing RNA they presented 
evidence that characteristic RNA foci form in a patient derived lymphoblastoid cell line 
(LCL).  Gel shift assays and immunofluorescence analysis suggests that the RNA binding 
protein SRSF2 interacts with TG3C2 RNA and is sequestered into RNA foci.  In a follow 
up study, Liu et al. demonstrated that these foci are present throughout the CNS of SCA36 
patients (Liu et al., 2014).  Interestingly, they noted that the size of the foci actually differed 
across regions and they could group the foci by size (small, medium, or large); large foci 
(i.e. >10 µm) were predominately in disease relevant cell types including Purkinje neurons, 
spinal motor neurons, and neurons of the olivary nucleus.  A more recent study generated 
patient derived stem cell models of SCA36 and demonstrated that RNA foci are present in 
both patient iPS and iPS derived neurons (Matsuzono et al., 2017).  Antisense 
oligonucleotides (ASO) developed to target the repeat expansion reduced RNA foci burden 
in both iPS and iPS derived neurons, thus providing proof-of-principle that ASOs could be 
a therapeutic strategy to mitigate RNA toxicity in SCA36.  
1.5.3 Neuropathology of SCA36 
Neuropathological findings are limited in SCA36.  To date, only two publications 
have reported post-mortem analysis of SCA36 patients (Liu et al., 2014; Obayashi et al., 
2015).  In their initial report of SCA36 post-mortem analysis, Liu et al., demonstrated that 
RNA foci were present in a number of CNS regions including Purkinje neurons, spinal 
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motor neurons, and neurons of the olivary nucleus (discussed in detail above).  
Immunohistochemistry for TDP-43 was negative throughout the CNS; however, the 
authors report the presence of large p62 and ubiquitin aggregates in the inferior olive.  In a 
second study by Obayashi et al., neuropathological examination of an asymptomatic patient 
harboring the SCA36 associated repeat expansion revealed diffuse cerebellar atrophy and 
mild Purkinje cell degeneration characterized by distorted dendrites and Purkinje cell 
“torpedos” (Obayashi et al., 2015).   Although immunohistochemical staining for ubiquitin, 
TDP43, FUS and p62 were unremarkable, the authors note that there were numerous 
amyloid plaques consistent with Braak Stage IV; it should be noted the patient was 90 years 
old at the time of autopsy.   
Presented in more detail in Chapter 2, work done in this thesis greatly expands our 
knowledge of the neuropathology associated with SCA36.  During this project, six SCA36 
post-mortem cases were obtained from collaborators around the world (see Table 2.1 in 
Chapter 2 for SCA36 cases used in post-mortem analysis).  To our knowledge these are the 
only SCA36 post-mortem cases known to date. 
1.5.4 Mouse Models of SCA36 
To date a mouse model of SCA36 has not been published; however, as a result of 




Figure 1.3: Putative Disease Mechanisms in SCA36. 
Putative disease mechanisms in SCA36 include 1) haploinsuffiency of the NOP56 gene, 
2) RNA-mediated toxicity via sequestration of RNA binding proteins, and 3) production 
of aberrant dipeptide repeats.  
 
1.6 Discussion, Thoughts, and Thesis Objectives 
The discovery of the c9ALS/FTD repeat expansion is undeniably a breakthrough in our 
understanding of ALS and FTD.  The prevalence of c9ALS/FTD in both familial and 
sporadic forms of ALS and FTD has placed significant importance on understanding how 
this mutation results in disease as well as on the development of therapeutic strategies to 
combat it.   
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Figure 1.4: Number of publications related to c9ALS/FTD and SCA36 since their 
discovery in 2011.  
  
Moreover, the type of mutation implicated in c9ALS/FTD, i.e. a repeat expansion, has no 
doubt promoted heightened interest and research in the field (Fig 1.4).  Investigators who 
previously studied other repeat expansion disorders or researchers with a focus on the 
development of tools and assays to study repetitive sequence elements have been 
invaluable to our understanding of c9ALS/FTD pathogenesis.  Despite numerous efforts, 
however, our understanding of the fundamental biology of how the G4C2 repeat expansion 
results in ALS and/or FTD remains elusive.  In my opinion, increased efforts indeed 
provide insight into disease pathogenesis, but perhaps paradoxically, also make it more 
difficult to separate wheat from chaff.  I believe our ability to converge upon a disease 
mechanism in c9ALS/FTD is confounded by  
1) The number of putative disease mechanisms plausible in a repeat expansion 
disorder.  The heterogeneity of a clinical condition caused by a repeat expansion 
lends itself to the idea that multiple disease mechanisms may be in play. Particularly 
in the case of c9ALS/FTD, where two clinically disparate disorders can occur, it is 
highly plausible that while one pathomechanism contributes to the development of 
ALS, a completely separate mechanism gives rise to the FTD phenotypes.   
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2) Inconsistencies of c9ALS/FTD animal models.  For example, in some animal 
models, RNA foci are toxic, in others the dipeptide repeats are toxic; Furthermore, 
multiple c9BAC mouse models lack any robust behavioral or motor phenotypes yet 
exhibit “toxic” cellular phenotypes such as RNA foci and dipeptide repeats. This is 
particularly confusing since the c9BAC mouse models are arguably more 
physiologically similar to the human mutation, and thus should, in theory, more 
faithfully represent the human condition.   
3) Lack of proper controls to identify disease relevant changes in the underlying 
biology.  Leading hypotheses of c9ALS/FTD pathogenesis are based on gain of 
function toxic mechanisms.  This begs the question, what are the proper controls to 
tease out disease relevant and specific mechanisms?   
This last point further raises an interesting question...what is it about the G4C2 repeat 
expansion specifically that results in cellular death and subsequently ALS and/or 
FTD?  Would the G4C2 repeat expansion result in c9ALS/FTD if it were placed in a 
different context?   More specifically, would the G4C2 repeat expansion cause disease if it 
was located in another intron of C9orf72?  Or if it was located in the first intron of a 
different gene?  While easy to formulate, these questions are considerably more difficult 
to answer.  The technical challenges associated with working with massively expanded 
sequences, let alone a sequence that is 100% GC rich limits our ability to address these 
questions in a disease relevant context.  These questions and challenges prompted me to 
ask whether there are hexanucleotide repeat expansions similar to the G4C2 repeat 
expansion in c9ALS/FTD that could be used to tease out disease specific mechanisms.  
Surprisingly, the highly related TG3C2 repeat expansions had recently been implicated in 
SCA36.  Differing by one base pair in the repeating unit, the SCA36 and c9ALS/FTD 
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repeat expansion are strikingly similar; they are both GC rich, intronic hexanucleotide 
repeats and they are both massively expanded in patients (hundreds to thousands of repeats 
on average).  While considerably understudied, investigations into SCA36 will 
undoubtedly aid in our understanding of c9ALS/FTD.   
Therefore, the overarching objective of this thesis was to provide a comprehensive 
comparison of these genetically similar, yet clinically disparate disorders and provide 
mechanistic insight into the disease pathogenesis of c9ALS/FTD and SCA36.  More 
specifically, I sought to provide insight into the role and toxicity of dipeptide repeats in 
these repeat expansion disorders.  Furthermore, I aimed to compare RNA-protein 
interactions between the c9ALS/FTD and SCA36 associated repeats in order to tease out 
disease specific interactions.  Lastly, given the strikingly different clinical phenotype 
between c9ALS/FTD and SCA36, I sought to elucidate gene expression signatures specific 
to each disorder in disease relevant regions.    
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CHAPTER 2. DIVERGENT DIPEPTIDE REPEAT PATHOLOGY 
IN C9ALS/FTD AND SCA36  
2.1 Divergent dipeptide repeat pathology in c9ALS/FTD and SCA36 
Several lines of evidence suggest that the translation of toxic homopolymeric peptides 
may contribute to disease phenotypes in a number of microsatellite repeat expansion 
disorders (Banez-Coronel et al., 2015; Mori et al., 2013b; Todd et al., 2013; Zu et al., 2017; 
Zu et al., 2011).  This includes the breakthrough discovery that GGGGCC hexanucleotide 
repeat expansions (HRE) in C9orf72, which cause amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD), lead to the production of aggregating dipeptide repeat 
(DPR) proteins via repeat associated non-AUG (RAN) translation (Kwon et al., 2014; 
Mizielinska et al., 2014; Zhang et al., 2018; Zhang et al., 2016).  Here we show that the 
related intronic GGCCTG HRE (alternatively denoted as TGGGCC) that causes 
spinocerebellar ataxia type 36 (SCA36) is also translated into DPRs, including poly(GP) 
and poly(PR), which are present in C9orf72-associated ALS/FTD (c9ALS/FTD).  We 
found that although poly(GP) is more abundant in SCA36 patient tissue compared to tissues 
from c9ALS/FTD patients, it exists as a soluble protein species and does not form insoluble 
aggregates as in c9ALS/FTD.  However, the frequency of the antisense RAN translation 
product poly(PR) is comparable between SCA36 and c9ALS/FTD patient postmortem 
samples.  TDP-43 pathology is yet another hallmark feature of c9ALS/FTD, and the 
mechanisms by which the GGGGCC HREs cause TDP-43 abnormalities remain an 
important question to be answered.  SCA36 patients do not exhibit TDP-43 pathology, 
suggesting that DPRs alone are insufficient to induce this disease-relevant correlate of 
c9ALS/FTD.  These findings reveal key differences in translation, solubility and protein 
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aggregation of DPRs between SCA36 and c9ALS/FTD and implicates alternate 
mechanisms for how highly similar repeat expansions can cause markedly distinct forms 
of neurodegeneration. Ultimately, these results expand our understanding of DPR 
pathology and their role in neurodegeneration. 
2.1.1 The SCA36 associated TG3C2 expansion is translated into dipeptide repeats 
Translation across the TG3C2 repeat results in six putative DPR protein species: poly(GP), 
poly(WA), and poly(GL) in the sense direction and poly(GP), poly(PR), and poly(AQ) in 
the antisense direction (Fig 2.1A).  Two of these putative DPRs, poly(GP) and poly(PR), 
are also translated via a RAN mechanism in c9ALS/FTD(Gendron et al., 2013; Mori et al., 
2013b).  To determine whether the TG3C2 repeat could undergo RAN translation in vitro, 
we generated NOP56 minigenes containing increasing number of TG3C2 repeats (Fig 2.7A, 
B).  Using a quantitative poly(GP) immunoassay (Gendron et al., 2017; Gendron et al., 
2015) we found that translation across the TG3C2 repeat is length-dependent and must meet 
a certain repeat-length threshold before it can occur (Fig 2.7C).  We could detect the 
presence of all sense reading frame DPRs through immunoblotting or 
immunocytochemistry against frame-specific c-terminal tags (Fig 2.7D, E).  These 
findings demonstrate that the intronic TG3C2 repeat can undergo RAN translation to 
produce DPRs in SCA36.  To test this hypothesis in a disease-relevant context, we 
developed multiple patient-derived cellular models of SCA36.  Quantitative immunoassays 
revealed that poly(GP) is detectable in SCA36 patient cells.  Strikingly, compared to 
c9ALS/FTD patient fibroblasts, poly(GP) was significantly increased in SCA36 patient 
fibroblasts (Fig 2.1B).  A similar relative increase in poly(GP) abundance was also seen in 
SCA36 induced pluripotent stem (iPS) cells, lymphoblastoid cell lines (LCLs), and 3D 
forebrain organoids (day 105).  Of interest, poly(GP) abundance in iPS-derived motor 
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neurons (iPS-MNs) was comparable between c9ALS/FTD and SCA36 samples (Fig 2.1C- 
F). 
2.1.2 Divergent DPR pathology in SCA36 and c9ALS/FTD 
Given the significant increase in detectable poly(GP) DPRs in cellular models of SCA36, 
we assessed whether poly(GP) is present in SCA36 postmortem tissue.  Poly(GP) was 
present in all evaluated regions of the central nervous system (CNS) (Fig. 2.2A), and 
poly(GP) abundance was comparable in the majority of neuroanatomical regions tested.  
However, there was a striking increase of poly(GP) in the dentate nucleus of the 
cerebellum, a region primarily affected in SCA36(Arias et al., 2017; Liu et al., 2014).  We 
next compared the poly(GP) burden in disease relevant CNS regions from c9ALS/FTD and 
SCA36 cases (Fig 2.2B-E).  Although poly(GP) abundance in the cerebellar cortex of 
SCA36 cases were comparable to c9ALS/FTD cases, there was a marked increase of 
poly(GP) in the frontal cortex of SCA36 patients, a result supported by the increased 
poly(GP) detected in iPS-derived 3D forebrain organoid models (Fig 2.1E).  Additionally, 
poly(GP) abundance in the spinal cord and the cerebellar dentate nucleus of SCA36 
patients was greater than in c9ALS/FTD.  These findings prompted us to assess the relative 
mRNA expression of NOP56 and C9orf72 in neural tissues obtained from healthy control 
samples.   Relative to C9orf72 mRNA levels, NOP56 mRNA is expressed at similar levels 
in the cerebellar cortex, a neuroanatomical region with comparable poly(GP) abundance in 
patients with SCA36 or c9ALS/FTD. In contrast, NOP56 expression is significantly higher 
than C9orf72 expression in the frontal cortex, cerebellar dentate nucleus, and spinal cord, 
three regions in which poly(GP) is likewise higher in SCA36 compared to c9ALS/FTD. 
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A neuropathological hallmark of c9ALS/FTD is the aggregation of both sense and 
antisense DPRs in patient postmortem tissue (Ash et al., 2013; Gendron et al., 2013; Mori 
et al., 2013b; Zu et al., 2013).  Since poly(GP) was detectable in lysates from postmortem 
tissues from SCA36 patients we investigated whether poly(GP) pathology was also present.  
Surprisingly, immunohistochemical analysis of poly(GP) in disease relevant regions of 
SCA36 did not reveal the characteristic poly(GP) aggregates seen in c9ALS/FTD (Fig 
2.2F, Fig 2.8).  The lack of poly(GP) aggregation was supported by the absence of 
pathology for ubiquitin-binding protein p62/SQSTM1, a common component of protein 
aggregates (Bjorkoy et al., 2006).  Although detectable by immunoassay, poly(GP) did not 
form insoluble inclusions in other CNS regions including the ventral horn of the spinal 
cord, hypoglossal nucleus of the medulla, inferior olive of the medulla, temporal cortex, 
occipital cortex, or parietal cortex (Fig 2.9, 2.10).  To further investigate the lack of 
poly(GP) aggregation in SCA36 we sequentially fractionated cerebellar and frontal cortex 
tissue samples using reagents of increasing solubilizing power.  Dotblot analysis for 
poly(GP) in the urea soluble fraction further supports the finding that poly(GP) is insoluble 
in c9ALS/FTD but exists in a soluble state in SCA36 (Fig. 2.2G).  Quantitative analysis of 
poly(GP) in each fraction revealed that it was predominately present in detergent soluble 
fractions in SCA36, and predominately present in the detergent insoluble, urea soluble 
fraction in c9ALS/FTD (Fig 2.2H, Fig 2.11).  Highly multiplexed, spatially resolved 
protein analysis (Digital Spatial Profiling; DSP) of the cerebellar granule, Purkinje, and 
molecular layers reveal layer specific divergent pathologies between c9ALS/FTD and 
SCA36 (Fig 2.2I, J ; Fig 2.12).  The presence of poly(GA) and p62 only in c9ALS/FTD 
cases confirms divergent DPR pathology.   Poly(GP) is also present in SCA36 as detected 
by immunoassay, however we failed to detect with DSP; this is consistent however, with 
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the lack of apparent poly(GP) via immunohistochemistry.  Interestingly, the RNA 
modification, N6-methyladenosine, as detected by an antibody to m6A, was significantly 
increased in the granule specifically of SCA36 but not in c9ALS/FTD.  
The chemical properties and lack of immunogenicity of the other putative sense DPRs, 
poly(GL) and poly(WA), precluded us from generating antibodies targeting these DPRs.  
However, using previously established polyclonal antibodies to poly(PR), an antisense 
DPR in c9ALS/FTD, we determined that poly(PR) formed aggregates in the granule cell 
layer of the cerebellar cortex in SCA36 (Fig 2.3A) and similar to c9ALS/FTD, poly(PR) 
aggregates were relatively rare.   In contrast to c9ALS/FTD, immunohistochemistry and 
immunoblots for phosphorylated TDP-43 in frontal cortex sections or urea fractions, 
respectively, demonstrates that SCA36 patients do not exhibit TDP-43 pathology 
characteristic of c9ALS/FTD (Fig 2.3B, C). 
2.1.3 Expanded TG3C2 repeats in the first intron of NOP56 are retained in SCA36 
Given the intronic nature of the SCA36 repeat expansion, we hypothesized that the 
massively expanded TG3C2 repeat impairs splicing of NOP56 and results in retention of 
the repeat containing intron 1.  To determine whether expanded TG3C2 repeats could impair 
splicing we adapted a split luciferase reporter that was previously developed to screen 
small-molecule modulators of splicing (Younis et al., 2010).  The full intron 1 sequence of 
NOP56 was modified to contain 2, 37, or 82 TG3C2 repeats and was inserted into the firefly 
luciferase ORF at an optimized splice site; defective splicing of the split luciferase reporter 
results in reduced luciferase activity (Fig 2.4A).  Relative to a NOP56 intron harboring 2 
TG3C2 repeats we saw a ~15% and ~25% reduction in luciferase activity in NOP56 introns 
harboring 37 and 82 TG3C2 repeats, respectively (Fig 2.4B).  This repeat-length dependent 
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reduction in luciferase activity suggests that expanded TG3C2 repeats in the context of the 
NOP56 intron 1 can impair splicing.  We next investigated whether intron 1 of NOP56 is 
retained in mRNA from SCA36 patient samples.  We designed custom Taqman qPCR 
probes spanning the exon 1 – exon 2 (ex1-2) splice junction (Fig 2.13A).  We reasoned 
that retention of intron 1 would prevent hybridization of the probe spanning the junction, 
thus resulting in a reduced qPCR signal.  We found a significant reduction in ex1-2 NOP56 
transcript levels (~40%) in the cerebellum of SCA36 patients (Fig 2.4C).  This reduction 
was consistent in patient-derived cellular models of SCA36 including fibroblast, iPS, and 
iPS-motor neurons (Fig 2.13B).  Interestingly, when we assessed NOP56 mRNA levels 
using probes spanning the downstream ex3-4 and ex6-7 splice junctions we found a marked 
increase in NOP56 transcripts in SCA36 compared to controls (Fig. 2.4C, 2.13B).  
Although unexpected, this finding is consistent with a recent study that demonstrated that 
the NOP56 protein is autoregulated by modulating the available pool of protein-coding 
NOP56 mRNA (Lykke-Andersen et al., 2018).  These findings provide evidence that 
massively expanded TG3C2 repeats impair splicing and result in retention of the repeat 
containing intron 1 of NOP56 in SCA36 patient. 
2.1.4 ATG-mediated translation preferentially drives production of poly(GP) DPRs in 
SCA36 
Retention of NOP56 intron 1 in SCA36 results in a new mRNA variant.  Unlike the 
C9orf72 intron 1 that is flanked by untranslated exons, the NOP56 intron 1 is flanked by 
coding exons.  Intron 1 of NOP56 is a phase 0 intron positioned immediately after the ATG 
start codon in exon 1.  This type of exon-intron structure is referred to as a  “start-codon 
intron” and is overrepresented in genes encoding highly conserved proteins such as the 
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ribosomal proteins (Nielsen and Wernersson, 2006; Yoshihama et al., 2002).   Given the 
ATG start site in the first exon, we hypothesized that retention of intron 1 would allow for 
AUG mediated translation of the expanded TG3C2 repeats in SCA36.  Interestingly, 
analysis of the NOP56 Refseq gene (NM_006392) reveals that AUG mediated translation 
of a retained intron transcript variant would produce a polypeptide containing repeating 
Gly-Pro units, i.e. poly(GP) frame (Fig 2.4D).  It should also be noted that the retained 
intron transcript variant maintains a perfect Kozak sequence (GCCATG|g, where | denotes 
exon-intron boundary).  Therefore, we sought to determine whether the ORF of a retained 
intron transcript variant specifically on the allele harboring TG3C2 expansions (“expanded 
allele”) are in frame with poly(GP) in SCA36 patients.  We performed repeat-primed PCR 
(RP-PCR) on gDNA isolated from SCA36 patient cerebellum.  RP-PCR amplicons were 
separated via gel electrophoresis and high-molecular weight amplicons were gel extracted, 
TOPO-cloned, and Sanger sequenced (Fig. 2.14A).  It is possible that RP-PCR would 
produce amplicons from the WT (non-expanded) allele as well; thus, to ensure that only 
amplicons specifically from the expanded allele were analyzed, we considered TOPO-
clone sequences that 1) contained a greater number of TG3C2 repeat units than the 
corresponding WT allele, as determined by sequencing of the WT specific allele and 2) 
contain the rs28970277 (-/CGGGCG) polymorphism in the intron region specific to the 
expanded allele haplotype ((Fig. 2.14A).  Similar to the NOP56 Refseq gene sequence, 
putative AUG mediated translation of the expanded allele would produce a poly(GP) 
containing peptide species (Fig 2.4D).  In light of this finding, it stands to reason that 
canonical AUG translation could drive production of the poly(GP) DPR in SCA36.  
Therefore, we next investigated how canonical AUG mediated translation in the GP frame 
(+0 frame) would affect translation of the other putative SCA36 specific DPR frames, 
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poly(GL) and poly(WA).  To this end we generated a number of translation reporter 
constructs that contained 23bp of NOP56 exon 1 and intron 1 containing 82 TG3C2 repeats 
followed by NanoLuc in either the +0, +1, +2 frame (Fig 2.4E).  As expected, translation 
in the +0 (GP) frame was most efficient and resulted in robust luciferase signal; however, 
luciferase signal in the +1 and +2 frames was significantly reduced.  Given that expanded 
TG3C2 repeats can undergo RAN translation (Fig 2.1A-D), we wanted to compare the 
efficiency of translation of the +1 and +2 frame associated DPRs in both canonical AUG 
mediated and non-canonical RAN translation mediated contexts.  The translational reporter 
constructs were modified by replacing the 23bp exon 1 of NOP56 with a 23bp sequence 
containing six stop codons (two stop codons per frame).  Notably, translation of the +1 and 
+2 frame is significantly reduced in a canonical AUG mediated context compared to the 
non-canonical RAN translation context (Fig. 2.4F).  Collectively, this data suggests that 
the retention of the repeat containing intron 1 of NOP56 in SCA36 results in a novel mRNA 
variant that promotes canonical AUG driven translation of poly(GP) DPRs in SCA36.  
Moreover, canonical translation preferentially produces the poly(GP) DPR relative to 
poly(GL) or poly(WA). 
2.1.5 Chimeric DPR species underlie divergent DPR pathology between SCA36 and 
c9ALS/FTD 
Next, we sought to determine the underlying mechanism that drives divergent dipeptide 
repeat pathology in pathology in c9ALS/FTD and SCA36.  Transient expression of GP80x-
GFP in HEK293T cells suggests that poly(GP) is a soluble peptide species (Fig 2.15A, B); 
however we wanted to assess whether poly(GP) remains soluble after long term expression 
in disease relevant cell types both in vitro and in vivo.  To this end, we generated an AAV 
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expressing GFP alone or GP80x-GFP.  Transduction of iPS-derived motor neurons with 
AAV-GP80x-GFP for 21 days revealed that poly(GP) remained diffuse throughout the cell 
including the cytoplasm, neurites, and nucleus (Fig 2.15C).  Since poly(GP) forms 
perinuclear inclusions in c9ALS/FTD, it is reasonable to posit that an in vivo component is 
required for the aggregation of poly(GP).  To address this, we expressed GFP or GP80x-
GFP in the mouse CNS via intracerebrventricular delivery.  Immunohistochemical analysis 
for poly(GP) in GP80x-GFP revealed diffuse poly(GP) staining throughout the CNS.  
Poly(GP) was diffuse in the cell bodies and dense dendritic neurites of Purkinje cells in the 
cerebellum as well as neurons of the frontal cortex (Fig 2.5A, Fig 2.15D) .  Notably, 
poly(GP) signal was robust throughout the neuropil which is consistent with poly(GP) 
being diffuse in the neurites in of iPS-derived motor neurons.  The c9ALS/FTD specific 
DPR, poly(GA) is highly aggregate prone, and unlike poly(GP), transient expression of 
GA encoding constructs in HEK293T cells form perinuclear inclusions.  Moreover, 
poly(GA) inclusions are highly abundant in c9ALS/FTD post mortem tissue.  We 
hypothesized that the aggregate prone propensity of poly(GA) may promote aggregation 
of poly(GP).  We performed dual-immunofluorescence for poly(GA) and poly(GP) in 
human c9ALS/FTD post-mortem tissue.  Similar to a previous report (Lee et al., 2017) we 
found that near 100% of poly(GP) aggregates co-localized with a poly(GA) inclusion, 
however only a fraction of poly(GA) aggregates co-localized with poly(GP) (Fig 2.5B).  
Co-localization of poly(GP) inclusions with poly(GA) further supports the hypothesis that 
poly(GA) mediates aggregation of poly(GP) in human post-mortem samples.  In light of 
this finding, we reasoned that poly(GA)-mediated aggregation of poly(GP) could result 
through two different mechanisms: 1) poly(GA) DPRs cross-seed aggregation of poly(GP) 
or 2) aberrations in the translation of the c9ALS/FTD associated G4C2 repeat results in the 
 34 
production of a chimeric dipeptide repeat (“cDPRs”) species consisting of GA and GP 
DPRs (Fig 2.5C).  To test this hypothesis, we generated a number of tagged constructs 
expressing DPRs alone, GA80x-GFP (“GA”), GA80x-HA (“GA-HA”), GP80x-GFP (“GP”) 
or a chimeric DPR construct expressing GA50xGP50x-GFP (“GAGP”).  
Immunofluorescence analysis for GFP reveals that chimeric GA50xGP50x-GFP peptides 
form perinuclear inclusions in HEK293T cells similar to GA80x-GFP; this is in contrast to 
the diffuse pattern seen with poly(GP) (Fig 2.5D).  While we see co-localization of GA80x-
HA and GP80x-GFP when co-transfected in HEK293T cells, it is unclear whether this co-
localization is in fact due to co-aggregation of these DPRs or rather a weak hydrophpbic 
interaction.   To address this question, we investigated whether GA80x-GFP (“GP”), GP80x-
GFP (“GA”), co-transfection of GA80x-HA and GP80x-GFP (“GA + GP”), or chimeric 
GA50xGP50x-GFP (“GAGP”) peptides reside in the soluble (1% triton-x) or insoluble (2% 
SDS) fraction.  As expected, immunoblots for GFP reveal poly(GP) alone resides 
predominately in the soluble fraction, whereas poly(GA) resided in the insoluble fraction 
(Fig 2.5E).  Interestingly, co-transfection of GP80x-GFP and GA80x-HA demonstrates that 
poly(GP) in the presence of a separate poly(GA) peptide remains soluble.  In contrast, 
chimeric GA50xGP50x-GFP peptides are found in the insoluble fraction.  This suggests that 
co-localization of GA and GP as assessed by immunofluorescence may result from weak 
protein-protein interactions.  Furthermore, these data suggest that chimeric DPRs, which 
we termed “cDPRs” but not a combination of individual GA-GP interactions can promote 
the formation of insoluble poly(GP) inclusions as seen in human post-mortem tissue (Fig 
2.2F,H and Fig 2.5B).  We next investigated whether cDPRs occur in human post-mortem 
tissue samples.  In order to test our hypothesis, we developed a meso-scale discovery 
(MSD) immunoassay to detect chimeric DPR species (Fig 2.5F).  The sensitivity of this 
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immunoassay to specifically detect chimeric DPR species was tested by assaying 
HEK293T lysates expressing GP alone, GA alone, chimeric GAGP, or co-transfected GA 
and GP constructs.  We found that the chimeric MSD immunoassay specifically and 
robustly detects chimeric GAGP DPRs (Fig 2.5G).  Importantly, we found that chimeric 
GAGP DPRs could be detected in both detergent soluble and detergent-insoluble, urea-
soluble fractions in the cortex of c9ALS/FTD patients (n=4) (Fig 2.5H,I).  The absence of 
GAGP cDPRs in controls and SCA36 support the specificity of this assay to detect cDPRs.  
Collectively, these data provide evidence that the production of chimeric dipeptide repeats 
underlie the divergent DPR pathology between c9ALS/FTD and SCA36. 
2.1.6 Antisense oligonucleotides reduce poly(GP) in SCA36 cellular models 
Finally, we evaluated the therapeutic potential of antisense oligonucleotides (ASOs) to 
mitigate DPR burden in SCA36.  RNAse H-dependent ASOs were designed to target 
various regions of the NOP56 locus (Fig. 2.6A).  An initial screen in SCA36 fibroblasts 
transfected with 100nM ASOs for 48 hours revealed that ASOs specifically targeting the 
HRE-harboring intron 1 of the NOP56 locus significantly reduced poly(GP) abundance by 
~50% (Fig 2.6B).  Similarly, expression of NOP56 mRNA was reduced by intron 1 
targeting ASOs (Fig 2.6C).  Given the limitations of lipid-based delivery methods as a 
viable in vivo therapeutic option, we tested whether gymnotic delivery of ASOs could 
reduce poly(GP) in patient fibroblast and LCLs (Fig 2.6D).  We found that ASOs targeting 
the expanded repeat robustly reduced poly(GP).  Lastly, we demonstrate that poly(GP) is 
detectable in the cerebrospinal fluid (CSF) of SCA36 patients as observed in c9ALS/FTD 
patients(Gendron et al., 2017) (Fig 2.6E).  These results suggest that ASOs could be a 
potential therapeutic option for reducing repeat-RNA and DPRs in SCA36 and that 
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detection of poly(GP) in the CSF may prove to be a useful biomarker for ASO target 
engagement. 
2.1.7 Discussion 
Here we show that the intronic SCA36-associated TG3C2 repeat expansion can undergo 
RAN translation in both the sense and antisense direction to produce DPR proteins.  We 
found that poly(GP) levels were higher in SCA36 than in c9ALS/FTD, but that inclusions 
of poly(PR), reported to be highly toxic in several model systems (Kwon et al., 2014; 
Mizielinska et al., 2014), were rare in both SCA36 and c9ALS/FTD.  With regards to 
poly(GP), there is an AUG initiation site in the first exon of NOP56; it is thus possible that 
the increase in poly(GP) abundance in SCA36 results from a combination of non-canonical 
RAN translation and canonical AUG-mediated translation.  Of interest, despite poly(GP) 
abundance being higher in SCA36 than in c9ALS/FTD, poly(GP) is predominately soluble 
in SCA36 but predominately insoluble in c9ALS/FTD. These data suggests that a 
secondary mechanism initiates aggregation of poly(GP) in c9ALS/FTD.  Although 
poly(GP) is not overtly toxic in some cellular and animal models of c9ALS/FTD, these 
models are limited in their potential to study the long-term effect of poly(GP) burden.  
Moreover, it is possible that CNS regions with relatively high soluble poly(GP) burden in 
SCA36 such as the cerebellar dentate nucleus are less efficient in clearing DPRs and may 
in fact lead to their selective vulnerability in SCA36. 
A hallmark of c9ALS/FTD as well as sporadic and other genetic forms of ALS and FTD 
is the nuclear clearing of TDP-43 and the accumulation of phosphorylated and cleaved 
TDP-43 into cytoplasmic aggregates.  Previous studies have demonstrated that TDP-43 
pathology correlates with neurodegeneration and clinical phenotypes(Davidson et al., 
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2016).  Although a recent study demonstrated that c9ALS/FTD-associated DPRs can cause 
TDP-43 mislocalization in Drosophila (Solomon et al., 2018), previous work in mice 
provided evidence that poly(GA) (Zhang et al., 2016) and poly(GR) (Zhang et al., 2018) 
alone cannot promote the formation of TDP-43 inclusions.  Nevertheless, expression of the 
c9ALS/FTD-associated expanded G4C2 repeat in mice does cause TDP-43 pathology 
(Chew et al., 2015), suggesting that TDP-43 dysfunction in c9ALS/FTD results from a 
combination of various DPRs, from RNA-mediated toxicity or from some combination of 
these mechanisms.  Consistent with these data, we show that the presence of poly(GP) and 
poly(PR) are insufficient to cause TDP-43 pathology in SCA36. 
Overall, this study reveals key similarities and differences in the solubility and protein 
aggregation of DPRs between SCA36 and c9ALS/FTD and implicates alternate 
mechanisms for how highly similar repeat expansions can cause markedly distinct forms 
of neurodegeneration. Comparing these related yet different diseases provides us with a 
unique opportunity to address key questions about HRE-dependent neurodegeneration, and 





Figure 2.1: Poly(GP) is detectable in patient derived cellular models of SCA36. 
(A) Schematic of putative dipeptide repeats in SCA36.  (B to F) Immunoassay for poly(GP) 
in SCA36 fibroblast, lymphoblastoid cell lines (LCL), induced pluripotent stem cell (iPS), 
3D forebrain organoid (Day 105), and iPS-derived motor neurons (iPS-MNs).  Data are 
presented as mean ± SEM; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, (B-F) 
Kruskal-Wallis one way analysis of variance followed by pairwise Mann-Whitney test. 
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Figure 2.2: Poly(GP) is abundant but does not form insoluble inclusions in SCA36 
postmortem tissue. 
(A) polyGP is detectable throughout the CNS of SCA36 patients.  (B-E) polyGP is 
expressed at similar or increased abundance in SCA36 samples compared to c9ALS/FTD 
samples in disease relevant CNS regions.  (F) poly(GP) aggregates in c9ALS/FTD but not 
SCA36 patient postmortem tissue. Scale Bar: 100 µm.  (G) poly(GP) is detectable in the 
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urea soluble fraction of c9ALS/FTD but not SCA36 samples as assessed by dotblot.  (H) 
Quantitative immunoassay of sequentially fractionated tissue samples reveals poly(GP) 
predominately exist as a soluble protein species in SCA36 whereas in c9ALS/FTD a large 
fraction of poly(GP) exists in the insoluble fraction.   (I) Representative images of granule, 
Purkinje, and molecular cell layer ROI selection (white ouline) for digital spatial profiling 
of cerebellar samples.  Calbinding and DAPI were used to delineate cerebellar architecture.  
(J) Volcano plots illustrating differentially abundant proteins as determined by digital 
spatial profiling in the cerebellar granule layer of c9ALS/FTD and SCA36 compared to 
controls (n=7 c9ALS/FTD, n=5 SCA36, n=7 control cases).  Significant proteins (p<0.05) 
are colored.  (B-E) *p<0.05, **p<0.005, ***p<0.0005, Kruskal-Wallis one way analysis 




Figure 2.3: SCA36 contains polyPR aggregates but lacks TDP43 pathology. 
(A) The antisense DPR, poly(PR) aggregates in both c9ALS/FTD and SCA36 cerebellar 
tissue.  (B) SCA36 frontal cortex tissue lacks TDP43 pathology characteristic of 
c9ALS/FTD.  (C) pTDP43 is not found in the detergent insoluble, urea soluble fraction of 
SCA36 patient frontal cortex.  #cleavage products, *full-length TDP43, †oligomeric 
species, ‡high molecular weight species.    
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Figure 2.4: Expanded TG3C2 impair splicing and result in intron 1 retention of 
NOP56 in SCA36. 
(A) Schematic of split luciferase expression construct.  Intron 1 refers to the intron 1 
sequence of NOP56 containing 2, 37, or 82 TG3C2 repeats.  (B) Normalized expression (to 
2R) of split luciferase reporter constructs (n=2 biological replicates).  C) Relative 
expression of NOP56 using TaqMan probes spanning exon-exon junctions in control and 
SCA36 cerebellar cortex samples (n=20 control, n=5 SCA36).  (D) Alignment of the 5’ 
flanking sequence of intron 1 from the expanded allele of SCA36 cases.  (E) Schematic 
figure of (GGCCTG)82 NanoLuc (NLuc) reporter constructs.  (F) Expression of ATG 
(GGCCTG)82 NanoLuc reporter constructs (n=3 biological replicates).  Values normalized 
to co-transected firefly luciferase (FLuc).  (G) Expression of 6x Stop and ATG - 





Figure 2.5: Chimeric peptides underlie divergent DPR pathology in c9ALS/FTD and 
SCA36. 
(A) polyGP immunohistochemistry in AAV-GFP and AAV-GP80x-GFP.  polyGP remains 
soluble after 2 months in vivo.  (B) poly(GA) and poly(GP) colocalize in perinuclear 
aggregates in the frontal cortex of a c9ALS/FTD patient.  (C) Schematic illustrating 
putative mechanisms of poly(GA)-dependent poly(GP) aggregation.  (D) 
Immunofluorescence for GFP 48 hours after transfection in HEK293T cells expressing 
GP80x-GFP or chimeric GA50xGP50x-GFP to assess the aggregation propensity of a 
chimeric GAGP peptide.  (E) Immunoblot for the indicated proteins to determine whether 
GP80x-GFP, GA80x-GFP, chimeric GA50xGP50-GFP, or 1:1 co-transfection of GP80x-GFP 
and GA80x-HA is present in the  soluble (S) or insoluble (In) fraction.  (F) Schematic 
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illustrating the meso-scale discovery (MSD) immunoassay developed to detect chimeric 
DPRs.  (G) Chimeric GA/GP immunoassay was used to detect chimeric GAGP DPRs in 
HEK293T cells expressing either GP80x-GFP, GA80x-GFP, chimeric GA50xGP50-GFP, or 
1:1 co-transfection of GP80x-GFP and GA80x-HA.  (n=3 separate transfections) (H, I) 
Chimeric GA/GP immunoassay was used to detect chimeric DPRs in soluble (low salt 
buffer) or insoluble (urea) fractions from control (n=3), c9ALS/FTD (n=4), or SCA36 
(n=5) patient frontal cortex.  *p<0.05, **p<0.005, Kruskal-Wallis one way analysis of 




Figure 2.6: Antisense oligonucleotides reduce poly(GP) in patient derived cellular 
models of SCA36. 
(A) Schematic of ASOs targeting the SCA36 associated repeat expansion harboring intron 
1 of NOP56.  (B, C) SCA36 fibroblast were treated with 100nM non-targeting control ASO 
or an ASO targeting intron 1of NOP56 delivered via cationic-lipid mediated transfection.  
Protein lysates or RNA were collected 48hrs after treatment. n=3 replicates of one SCA36 
patient cell line.  (B) Relative poly(GP) levels from cell lysates after treatment.  (C) NOP56 
transcript levels after treatment.  (D) SCA36 fibroblast (n=2 patient cell lines) and LCLs 
(n=2 patient cell lines) were treated with 5µM non-targeting control ASO or an ASO 
targeting intron 1of NOP56 delivered via gymnosis.  Protein lysates were collected 10 days 
after treatment and poly(GP) levels measured. Data are presented as mean ± SEM; (B) to 
(E), *P<0.05, **P<0.01, ***P<0.001 one way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparisons test.  (E) poly(GP) in cerebrospinal fluid (CSF) from 
healthy controls (n=5) and SCA36 patients (n=9). 
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2.1.9 Supplemental Figures 
 
Figure 2.7: (Supplemental) Expanded TG3C2 repeats can undergo RAN translation 
in vitro. 
(A) Schematic figure of (TG3C2)n-3T constructs used for in vitro RAN translation studies.  
(B) Restriction digest and gel electrophoresis of (TG3C2)n-3T constructs containing various 
TG3C2 repeats.  (C) The expression of poly(GP) DPR protein in cells expressing expanded 
(TG3C2)n repeats is detectable by poly(GP) immunoassay.  (D) Immunofluorescence 
analysis of (TG3C2)n-3T constructs in HEK293T cells.  (E) Sense SCA36 DPRs can be 





Figure 2.8: (Supplemental) Lack of poly(GP) and p62-positive aggregates in SCA36 
patient postmortem tissue. 
Immunohistochemical staining of poly(GP) and p62/SQSTM1 in the cerebellar cortex and 
frontal cortex of control, c9ALS/FTD, and SCA36 patients (n=5 SCA36 cases).  Scale bars: 
50µm, inset 10µm 
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Figure 2.9: (Supplemental) Lack of poly(GP) aggregate in the inferior olivary 
nucleus of SCA36 patients. 
Poly(GP) aggregates are absent in the inferior olive in SCA36 patients as determined by 




Figure 2.10: (Supplemental) Lack of poly(GP) inclusions in SCA36 throughout the 
CNS. 
Lack of poly(GP) aggregates in the parietal cortex (A-A’’), occipital cortex (B-B’’), 




Figure 2.11: (Supplemental) Poly(GP) immunoassay of sequential fractions with 
increasing solubilizing power. 
 (A) Schematic of sequential fractionation protocol.  (B, C) Quantitative immunoassays for 
poly(GP) in each fraction.  Poly(GP) is most abundant in the low salt fraction in SCA36.  
Cb Ctx: cerebellar cortex.  Ft Ctx: frontal cortex. *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001 two-way analysis of variance (ANOVA) followed by Sidak’s multiple 




Figure 2.12: (Supplemental) Digital spatial profiling in the cerebellar cortex of 
c9ALS and SCA36. 
(A) Representative images of granule, Purkinje, and molecular cell layer ROI selection 
(white ouline) for digital spatial profiling of cerebellar samples.  Calbinding and DAPI 
were used to delineate cerebellar architecture.  (B) Volcano plots illustrating 
differentially abundant proteins as determined by digital spatial profiling in the cerebellar 
granule, Purkinje, and molecular layer of c9ALS/FTD and SCA36 compared to controls 






Figure 2.13: (Supplemental) Intron of NOP56 is retained in SCA36. 
(A) Schematic of NOP56 gene with relative locations of SCA36 associated repeat 
expansion and custom Taqman probes to assess splicing.  (B) qPCR for indicated Taqman 




Figure 2.14: (Supplemental) Outline of WT and expanded allele sequencing. 
(A) (1) Repeat-primed PCR (RP-PCR) was performed using unmodified oligonucleotides, 
(2) RP-PCR reaction products were separated on a 2% agarose gel.  In order to 
preferentially select amplicons for the exon 1 – intron 1 region of NOP56 from the 
expanded allele, high-molecular weight amplicons were gel extracted, (3) high-molecular 
weight amplicons were TOPO-cloned and Sanger sequenced.  (B) (1) PCR was performed 
using unmodified oligonucleotides to preferentially amplify the WT allele for the exon 1 – 
intron 1 region of NOP56, (2) PCR reaction products were separated on a 2% agarose gel 
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and single bands for the SCA36 cases were gel extracted, (3) amplicons were TOPO-cloned 
and Sanger sequenced.  (C) Alignment of the 5’ flanking sequence of intron 1 from the WT 
allele of SCA36 cases.  Numbers in parenthesis on the right side represent number of 
additional GGCCTG repeats from the WT allele.  (D) Table summarizing genotype data 
for the WT and expanded alleles in each SCA36 cases.  (E) Allelic discrimination plots for 




Figure 2.15: (Supplemental) poly(GP) is soluble in in vitro and in vivo models. 
(A) Immunofluorescence of GP80x-GFP transiently transfected in HEK293T cells for 48 
hours, (B) Immunoblot for indicated proteins of GP80x-GFP transiently transfected in 
HEK293T cells for 48 hours.  (C) AAV-mediated transduction of GP80x-GFP in iPS-
derived motor neurons for 24 days.  (D) Diffuse poly(GP) as detected in the cerebellar 




Figure 2.16: (Supplemental) Characterization of Control, c9ALS/FTD, and SCA36 
iPS lines. 
(A) Phase image of iPS colony morphology and immunofluorescence staining of 
pluripotent stem cell markers.  (B) RT-PCR analysis for mRNA expression of stem cell-
specific markers; early passage (<5) control iPS colony was used for the SEV positive 




Figure 2.17: (Supplemental) Schematic of the differentiation protocol and 
characterization of iPS-derived motor neurons (iPS-MNs). 
(A) Schematic of iPS-MN differentiation protocol.  (B) Phase images of embryoid bodies 
during differentiation and iPS-MNs at day 3 post dissociation.  (C) Immunofluorescence 
staining of motor neuron markers in iPS-MN.  (D) iPS-MNs express mir-218, a motor 
neuron specific microRNA.  (E) Quantification of islet1-positive iPS-MNs. 
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1 M 60 91 31 SCA SCA36 Spain 
2 M 60 95 35 SCA SCA36 Spain 
3 F 63 77 14 SCA SCA36 Spain 
4 F 83 90 7 SCA SCA36 France 
5 M 58 79 21 SCA SCA36 Japan 
6 M 57 86 29 SCA SCA36 Japan 
7 M 58 71 13 ALS/FTLD-TDP C9orf72 U.S.A. 
8 M 62 66 4 ALS/FTLD-TDP C9orf72 U.S.A. 
9 M 57 66 9 FTLD-TDP C9orf72 U.S.A. 
10 M 65 67 1.5 ALS/FTLD-TDP C9orf72 U.S.A. 
11 M 58 67 9 ALS/FTLD-TDP C9orf72 U.S.A. 
12 F 54 57 2.5 ALS/FTLD-TDP C9orf72 U.S.A. 
13 F 50 57 7 ALS/FTLD-TDP C9orf72 U.S.A. 
14 F 60 67 7 ALS/FTLD-TDP C9orf72 France 
15 M - 57 - Control - U.S.A. 
16 M - 70 - Control - U.S.A. 
17 M - 94 - Control - U.S.A. 
18 F - 57 - Control - U.S.A. 
19 F - 61 - Control - U.S.A. 
20 F - 91 - Control - U.S.A. 
21 F - 92 - Control - France 
ALS/FTLD-TDP=amyotrophic lateral sclerosis and frontotemporal lobar degeneration with TDP43 inclusions, 
SCA36=spinocerebellar ataxia type 36 
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Table 2.2: Sequence, target, and design of antisense oligonucleotides (ASOs) 
ASO Name Sequence NOP56 Target ASO Design 
Scrambled GCGACTATACGCGCAAUAUG Nontargeting 
• 5-10-5 Gapmer: 
 
• phosphorothioate backbone; 
 
• 2’-O-Me modifications on 5’ 
and 3’ wing; 
ASO-#1 GCGCCCCGCAACCACUCCUC Intron 1 
ASO-#2 CAGGCCCAGGCCCAGGCCCA (TG3C2) repeat 







CHAPTER 3. RNA-MEDIATED TOXICITY IN C9ALS/FTD AND 
SCA36 
3.1 RNA-mediated toxicity in repeat expansion disorders 
 Repeat containing RNA have been shown to interact and sequester RNA-binding 
proteins (RBPs), thus effectively reducing the available pool of functional RNA-binding 
proteins.  This putative disease mechanism has been proposed for a number of repeat 
expansion disorders (Zhang and Ashizawa, 2017); however, the most extensively studied 
and well-established example of RNA-mediated toxicity occurs in myotonic dystrophy 
type 1 (DM1).   In DM1, expanded CUG repeats in the gene DMPK1 form intranuclear 
RNA foci (Davis et al., 1997) and sequester the splicing associated RNA binding proteins 
Muscleblind 1 – 3 (MBNL1-3) (Miller et al., 2000).  Depletion of the MBNLs results in 
mRNA and miRNA misprocessing (Ho et al., 2004; Rau et al., 2011; Wang et al., 2012).  
Mouse models of DM1 mimic disease phenotypes seen in humans.  A homozygous 
transgenic mouse model expressing expanded CUG repeats in the context of the human 
DMPK gene developed cellular phenotypes such as intranuclear CUG foci as well as 
myotonia and progressive muscle weakness (Gomes-Pereira et al., 2007; Seznec et al., 
2000; Vignaud et al., 2010).  The MBNL KO model replicates many of the phenotypes 
seen in the transgenic CUG model, including clinically relevant features such as myotonia 
(Kanadia et al., 2003). This further supports the hypothesis that RNA-mediated depletion 
of MBNL may be the underlying mode of toxicity in DM1. These findings have been the 
basis for numerous studies investigating this mode of RNA-mediated toxicity in other 
repeat expansion disorders.  
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3.2 RNA-Protein Interactions in c9ALS/FTD and SCA36 
3.2.1 The c9ALS/FTD and SCA36 associated repeat expansions form atypical nucleic 
acid structures 
 The intronic hexanucleotide repeat, G4C2, implicated in ALS/FTD has been shown 
to form both DNA and RNA G-quadruplex structures (Fratta et al., 2012; Haeusler et al., 
2014b; Reddy et al., 2013; Su et al., 2014).  Since leading hypotheses in c9ALS/FTD rely 
on the idea that the atypical nucleic acid structures formed by expanded G4C2 repeats elicit 
cellular toxicity and initiate cascades of disease, it is critical to determine whether the 
SCA36 HRE forms similar atypical nucleic acid structures.  It is known that G-quadruplex 
containing nucleic acids are capable of interacting with and sequestering various RNA 
binding proteins, thereby preventing the proteins from functioning normally (Lee et al., 
2013b).  This model of RNA toxicity has been hypothesized to be a possible disease 
mechanism in c9ALS/FTD and recent studies have demonstrated, using a biotinylated 
RNA pulldown assay, that various RNA binding proteins indeed interact with G4C2 repeats 
(Donnelly et al., 2013b; Lee et al., 2013b).  This, mechanism has not been explored in 
SCA36.  Knowledge of the structure and stability of the SCA36 HRE compared to the 
c9ALS/FTD HRE will allow us to better understand why shared or unique proteins are able 
to interact and potentially be sequestered by one or both of the HREs. This understanding, 
coupled with validation of either similar or different toxicities of these repeats in in vitro 
models, will allow us to test more targeted hypotheses and elucidate why these two similar 
HREs lead to clinically different phenotypes. 
In collaboration with the Hud group at GaTech, we used CD spectroscopy, to demonstrate 
that (TG3C2)8 RNA forms a parallel G-quadruplex structure as evidenced by a 
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characteristic peak at 263nm and trough at 240nm; similar to the c9ALS/FTD associated 
(G4C2)8 RNA (Fig 3.1).   
 
Figure 3.1: CD spectra of G4C2 and TG3C2 RNA oligonucleotides 
CD spectra shows K+ - dependent RNA G-quadruplex formation with (G4C2)8 and 
(TG3C2)8 repeats. 
To further investigate whether (TG3C2)8 oligonucleotides can form non-canonical 
structures we employed an enzymatic assay, referred to as a G-quadruplex-hemin 
DNA/RNAzyme assay.  Numerous studies have shown that stacked G-tetrads structures 
can bind and activate hemin, thus promoting the hemin-mediated peroxidation reaction 
(Cheng et al., 2009; Li et al., 2016).  This technique has been used in recent studies to 
assess the ability of the c9ALS/FTD associated G4C2 repeat to form G-quadruplex 
structures (Grigg et al., 2014; Haeusler et al., 2014a).  Surprisingly, we found that unlike 
(G4C2)8 repeats, the (TG3C2)8 repeat is unable to bind hemin and facilitate its peroxidase 
activity (Fig 3.2A).  In support of this finding, the (G4C2)8 repeats but not the (TG3C2)8 
were able to bind a G-quadruplex triggered fluorogenic dye (ISCH-oa1) (Chen et al., 2016) 
(Fig 3.2B).   The discrepancy between the spectroscopic and enzymatic/fluorogenic G-
quadruplex results for the SCA36-associated TG3C2 repeat is intriguing.  The G-
quadruplex-hemin DNA/RNAzyme assay is mediated by binding of hemin on the planar 
surface of the stacked G-tetrads (Alizadeh et al., 2017), therefore these data suggest that 
despite forming a G-quadruplex, the structure of the TG3C2 prevents it from interacting 
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with hemin.  Extending this observation to a cellular system, it stands to reason that 
structures formed from G4C2 and TG3C2 repeats would potentially interact with unique 
proteins, in addition to several overlapping proteins. 
 
 
Figure 3.2: Enzymatic and fluorogenic G-quadruplex assays reveal divergent 
structural properties between the c9ALS/FTD and SCA36 associated repeats. 
(A) G-quadruplex-hemin DNA/RNAzyme assay. (G4C2)8, but not (TG3C2)8 can bind and 
activate hemin. Left: images of colorimetric changes.  Right: UV-Vis spectroscopy of 
10µM (G4C2)8, (TG3C2)8 and (CAG)16 repeats.  (B)  Fluorescence spectroscopy of 2µM 
(G4C2)8, (TG3C2)8 and (CAG)16 incubated with 1 µM ISCH dye. 
 
3.2.2 The c9ALS/FTD and SCA36 associated repeat expansions interact with a shared 
and unique subset of RNA binding proteins. 
Previous studies have demonstrated that the c9ALS/FTD-associated G4C2 HRE can form 
both DNA and RNA G-quadruplexes (Haeusler et al., 2014a; Reddy et al., 2013; Zamiri et 
al., 2014) and that G4C2 RNA oligonucleotides can interact with a number of RNA-binding 
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proteins (RBPs) (Cooper-Knock et al., 2014; Donnelly et al., 2013a; Haeusler et al., 2014a; 
Mori et al., 2013a); however, these studies together have identified over >900 different 
potential RNA-interacting proteins (Haeusler et al., 2016), an intractable number to test 
each interactor independently. Noting the sequence similarity and comparable HRE size 
between c9ALS/FTD and SCA36 patients, we hypothesized that comparison of proteins 
sequestered uniquely by c9ALS/FTD and not SCA36-associated repeats would allow 
us to narrow down sequestered proteins relevant to c9ALS/FTD pathogenesis. Using 
a protein microarray containing over 19,000 human proteins, we performed an unbiased 
RNA-protein interaction screen (Fig. 3.3A, B).  Unique to our study is the experimental 
design of our RNA-protein microarray screen: 1) The SCA36 associated repeat, TG3C2, 
was used as the control/normalizing probe instead of a scrambled control, 2) Both the 
c9ALS/FTD and SCA36 associated probes were analyzed on the same array, 3) We 
performed each screen both in the absence and in the presence of physiological levels of 
KCl (a cation required for G-quadruplex stability), 4) Each screen was performed in 
duplicate and the repeat associated fluorophore was switched for each replicate. Our results 
showed that G4C2 and TG3C2 RNAs share common interacting proteins, but they also 
bind to a unique set of RNA-binding proteins (Fig. 3.3C). Interestingly, in the presence 
of KCl, the number of total G4C2 repeat protein interactions increased considerably (Fig. 
3.3D), suggesting that a subset of these proteins interact in a structure dependent manner.  
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Figure 3.3: Both c9ALS/FTD and SCA36 HRE form G-quadruplexes and interact 
with similar, but also unique RNA binding proteins.  
(A) Schematic showing the experimental design of the RNA-protein interaction 
microarray. (B) Total number of hits identified. (C) Venn diagram of overlapping and 
unique RNA binding interactors between the G4C2 and fluorescence intensities for 
(G4C2)8 and (TG3C2)8 RNA.  (D) Number of proteins identified for the (G4C2)8 RNA in 
the absence and presence of KCl. 
Similar to previous studies, an intractable number of “positive” hits were identified using 
this RNA-protein microarray approach.  Moreover, the proteins on the microarray may 
have different abundances in different tissues and thus some RNA-protein interactions may 
be irrelevant when considering a particular cell/tissue type.  Therefore, we reasoned that 
cross-referencing putative RNA-protein interactors with RNAseq expression data from 
iPS-derived motor neurons (iPS-MNs) would allow us to narrow down disease relevant 
interactors.  To this end we performed RNA-seq on day 14 iPS-MNs generated from non-
expansion control patients and cross-referenced genes expressed in iPS-MNs to proteins 
we identified as specific interactors of G4C2 repeats. Approximately 50% of unique G4C2 
interacting proteins identified in our protein microarray were indeed expressed in motor 
neurons thus significantly reducing the number of proteins to consider (Fig 3.4A-B).  
Furthermore, ranking of RNA-protein interactors by relative gene expression and repeat 
specificity resulted in a more concise list of top candidates to pursue for further analysis 
(Fig 3.4D).  Interestingly, a number of motor neuron expressed, G4C2 specific interactors 
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are involved in alternative splicing (e.g. HNRNPD) and oxidative stress (e.g. PIP4K2B), 
pathways implicated in ALS pathogenesis (Barber and Shaw, 2010; Geuens et al., 2016).   
 
Figure 3.4: RNAseq analysis of iPS-derived MNs reveal motor neuron specific G4C2 
interactors. 
(A) Schematic of iPS motor neuron differentiation. (B) RNAseq analysis of iPS-derived 
MNs reveal a MN specific transcriptome profile.  (C) Venn diagram of unique G4C2 
interactors (+ KCl) and motor neuron expressed genes.  (D) Ranking of repeat specific 
interactors by relative gene expression (TPMs) in iPS-derived motor neurons (only genes 
with TPM >150 shown).  For ranking, only expression profiles of control (N=3) iPS-motor 
neurons were used. 
3.2.3 Development of an MS2-MCP in vitro model to identify RNA-protein interactions 
Although these data support this approach to compare RNA-protein interactions in the 
c9ALS/FTD and SCA36, to date, studies have not been conducted with G4C2 repeat sizes 
believed to be disease relevant, i.e. ≥30 repeats in a cellular system (Donnelly et al., 2013b; 
Lee et al., 2013b); instead, these interactions have only been explored using synthesized 
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short repeat RNAs after incubation with protein extracts from cells/tissues or protein 
arrays. We believe that using (G4C2) constructs of pathologic size to study RNA-protein 
interactions in disease-relevant model organisms will allow us to better understand the 
molecular cascades that initiate neurodegeneration in c9ALS/FTD.   
In order to capture TG3C2 and G4C2 specific RNA-protein interactions we proposed to use 
the MS2-MCP tagging system.  The MS2 aptamer is 23nt long RNA stem-loop sequence 
that binds with high affinity to the E. Coli bacteriophage MS2 coat protein (MCP).  When 
the aptamer is added to an RNA sequence of interest, the RNA can be visualized or isolated 
via  the MS2 coat protein (Bardwell and Wickens, 1990).   The MS2 system has been used 
in a number of studies specifically to capture RNA binding proteins (Slobodin and Gerst, 
2011), and in a recent study it was used to visualize phase transitions of RNA foci in 
myotonic dystrophy type 1 and c9ALS/FTD (Jain and Vale, 2017). In addition to the MS2 
aptamer system, a number of techniques to capture specific RNA-protein interactions have 
been developed including biotin tagging of in vitro transcribed RNA (Grabowski and 
Sharp, 1986), PP7 aptamer tagging (Carey et al., 1983), S1/D8 aptamer tagging (Srisawat 
and Engelke, 2001) and more recently the CRISPR/Csy4 system (Lee et al., 2013a). 
Our repeat tagged MS2-MCP system was composed of two parts:  1) Plasmids expressing 
either G4C2 or TG3C2 repeats with 3’ 24x MS2 stem loop repeats and 2) a stable HEK293T 
cell line expressing a tandem MCP-HaloTag fusion.  A number of considerations were 
taken into account when developing this system.  Typical MS2 stem-loop sequences are 
highly repetitive and technically challenging to manipulate.  Moreover, the GC rich nature 
of G4C2 or TG3C2 repeats make them equally difficult to manipulate and they are 
notoriously prone to recombination during plasmid propagation.  Therefore to circumvent 
the potential complications associated with tagging repetitive sequences with additional 
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repetitive stem loop sequences, we took advantage of a recently developed synonymous 
MS2-stem loop, MBSV5 (Wu et al., 2015).  These stem loop sequences were designed via 
a SELEX based approach to maintain high affinity binding with MCP but minimize 
repetitive loop structures.  We generated (G4C2)2 control, (G4C2)66 pathogenic, (TG3C2)2 
control, and (TG3C2)82 pathogenic constructs containing 24x MBSV5 stem loops at the 3’ 
end (3.5 A,B).  Next, we developed a stable HEK293T cell line expressing a tandem MCP 
fused to HaloTag (tdMCP-Halo).  The MS2-MCP system is most commonly used to 
visualize single molecule RNAs in the cytoplasm thus most MCP proteins are engineered 
to contain a nuclear localization sequence (NLS) in order to promote cytoplasmic clearance 
of unbound MCP proteins and reduce background signal in the cytoplasm (Fig 3.6A).  
However, repeat containing RNA form intranuclear foci which are thought to be potential 
sites of RNA toxicity.  We found that inclusion of an NLS on MCP-HaloTag resulted in 
excess background signal in the nucleus and we could not visualize distinct RNA foci (data 
not shown).  Therefore, in order to promote both nuclear and cytoplasmic distribution of 
the MCP-HaloTag while minimizing nuclear background signal, we added a strong nuclear 
export signal and a weak nuclear localization signal.  Fluorescence microscopy revealed 
diffuse nuclear and cytoplasmic distribution of tdMCP-HaloTag (Fig 3.6D).  Transient 
expression of MS2-tagged G4C2 repeats in the stable MCP-HaloTag HEK293T cell line 
and subsequent visualization by addition of the Halo binding dye, TMR, demonstrated that 
only G4C2 repeats of pathogenic length formed distinct intranuclear foci, similar to what is 




Figure 3.5: MS2-tagged RNA affinity pull-down (MS2-TRAP) assay to identify RNA 
binding proteins interacting with G4C2 or TG3C2 repeat RNAs. 
(A)   Restriction digest of (G4C2)-MS2 constructs. (B)  Schematic of (G4C2)-MS2/MCP-
HaloTag system.  (C)  MCP-HaloTag was transiently transfected into HEK293T cells alone 
or with (G4C2)-MS2 constructs.  Live-cell visualization of HaloTag using the TMRdirect 
ligand show distinct formation of RNA foci (arrow) in the 66 repeat constructs but not the 
2R constructs. (D)  RNA fluorescent in situ hybridization using an LNA probe targeting 





Figure 3.6: Development and characterization of a stable MCP HEK293T cell line. 
(A) Schematic illustrating localization signal considerations for MCP construct.  (B) qPCR 
using Taqmans targeting either the HaloTag sequence or MCP sequence in the parental 
HEK293T and stable TdMCP-Halo HEK293T cell line.  No amplification in parent 
HEK293; Ct values set at 40 for graphical purposes.  (C) RT-PCR of HaloTag sequence 
and immunoblots for indicated proteins reveals expression of TdMCP-HaloTag.  (D) 
Fluorescence microscopy for the HaloTag binding dye, TMR demonstrates that the 
TdMCP-HaloTag protein localizes to both the nucleus and cytoplasm. 
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CHAPTER 4. GENERAL DISCUSSION 
4.1 Summary 
 In the preceding chapters I sought to provide mechanistic insight into the 
hexanucleotide repeat expansions disorders, c9ALS/FTD and SCA36.  More specifically, 
I hoped to gain a better understanding of how proposed gain-of-function toxic mechanisms 
may contribute to neurodegeneration in these two disorders.  The genetic mutations 
underlying these two clinically distinct disorders are highly similar in sequence and 
location.  Therefore, I hypothesized that a comprehensive and comparative analysis of 
molecular phenotypes in c9ALS/FTD and SCA36 would provide a unique opportunity to 
gain a thorough understanding of common and disease-specific pathomechanisms in these 
two disorders.  In Chapter 2 I demonstrated for the first time that the SCA36 associated 
TG3C2 repeat expansion can be translated into both sense and antisense dipeptide repeats.  
Furthermore, I provided evidence from patient brain tissue that chimeric, aggregate-prone 
DPRs are produced specifically in c9ALS/FTD, which may explain the divergent 
pathology between SCA36 and c9ALS/FTD  In Chapter 3 I demonstrated that the 
c9ALS/FTD and SCA36 repeat expansions interact with shared and unique subsets of 
RNA-binding proteins, and I developed an in vitro model to further study RNA-protein 
interactions in a disease relevant context.  Additionally, I used targeted and whole 
transcriptome sequencing to understand which molecular pathways are disrupted in the 
CNS of patients with repeat expansion disorders.  Future studies I intend to pursue will 
further two key findings from this thesis and be focused on: 1) defining the role of chimeric 
dipeptide repeats in the pathogenesis of c9ALS/FTD and related repeat expansions and 2) 
defining the role of RNA-mediated toxicity in the development of TDP-43 pathology in 
c9ALS/FTD.  I believe this comparative approach to study repeat expansions that are 
similar in sequence but result in vastly different clinical presentations will aid in our 
understanding of other microsatellite expansion disorders.  Lastly, I hope the knowledge 
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generated from this thesis will prove useful in the development of therapeutic strategies to 
combat these devastating disorders. 
4.2 The role of DPRs in the pathogenesis of c9ALS/FTD and SCA36 
The discovery that microsatellite repeat expansions in non-coding regions of a gene 
can undergo non-canonical translation to produce homopolymeric peptides (Zu et al., 2011) 
prompted significant interest in whether these peptides could contribute to 
neurodegeneration.  Indeed, subsequent studies have provided evidence that 
homopolymeric peptides are produced and elicit toxicity in several microsatellite 
expansion disorders (Banez-Coronel et al., 2015; Mizielinska et al., 2014; Sellier et al., 
2017; Zu et al., 2017).  In c9ALS/FTD, a number of mechanisms by which dipeptide 
repeats induce neurotoxicity have been proposed including inhibition of the ubiquitin-
proteasome system (May et al., 2014), disruption of nucleocytoplasmic transport (Jovicic 
et al., 2015; Shi et al., 2017), impairment of stress granule dynamics (Boeynaems et al., 
2017; Lee et al., 2016a; Zhang et al., 2018) and more recently mitochondrial dysfunction 
(Choi et al., 2019).  Furthermore, long-term CNS expression of poly(GA), -(GR), or -(PR) 
in mice result in behavioral and motor impairments.  Nonetheless, the overt toxicity 
associated with DPRs in model systems contrast to observations made in human 
c9ALS/FTD patients.  While it is possible (and perhaps even likely) that DPRs contribute 
in some manner to the vulnerability of certain neuronal and/or non-neuronal populations, 
their exact role in the pathogenesis of ALS and/or FTD remain elusive.  Here, I discuss a 
number of points that I believe are important in the consideration of dipeptide repeat 
toxicity in c9ALS/FTD and in totality suggest that DPRs do not directly promote 
neurodegeneration in c9ALS/FTD.  
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DPR burden and neurodegeneration:  Dipeptide repeats, especially poly(GA) and 
poly(GP),  have been detected throughout the CNS in c9ALS/FTD including in the frontal 
cortex, cerebellum, motor cortex, and hippocampus  (Al-Sarraj et al., 2011; Cooper-Knock 
et al., 2012; Troakes et al., 2012; Vatsavayai et al., 2019).  Although they have been 
detected, DPR inclusions are rare in the spinal cord (Gomez-Deza et al., 2015); likewise in 
this study we found that poly(GP) levels in the spinal cord of c9ALS/FTD cases were 
comparable to the background signal detected in controls (see Chapter 2, Fig 2.2E).  It is 
possible that the lack of DPRs in the spinal cord of patients could be attributed to the 
significant loss of motor neurons at autopsy.  In contrast to the spinal cord, in CNS regions 
unaffected in c9ALS/FTD (e.g. the granule layer of the cerebellum) the abundance of 
DPRs, particularly poly(GA) and poly(GP), is striking.  It is not unreasonable, therefore, 
to speculate that the cerebellum and cerebellar associated function would be significantly 
affected if DPR inclusions alone were sufficient for neurodegeneration. 
Relevance of arginine-rich DPRs:  The arginine rich DPRs, poly(GR) and poly(PR) are 
undoubtedly toxic in model systems (Kwon et al., 2014; Mizielinska et al., 2017; Zhang et 
al., 2018; Zhang et al., 2019).  However, both DPRs, particularly the antisense poly(PR), 
are rare relative to poly(GA) and poly(GP).  Moreover, in this thesis (see Chapter 3, Fig 
3.1A) we provide evidence that the antisense DPR, poly(PR), is also present in SCA36, a 
clinically distinct disorder from c9ALS/FTD.  Furthermore, previous studies have not been 
able to correlate poly(GR) or poly(PR) to neurodegeneration (Davidson et al., 2016; 
Mackenzie et al., 2015; Schludi et al., 2015), although a recent report demonstrated that 
poly(GR) correlates with neurodegeneration in the specific clinicopathological subtype, 
FTLD-MND; however, this correlation was only seen in the hippocampus (Sakae et al., 
2018).  Despite being toxic in model systems, the relatively low abundance of arginine rich 
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DPRs in patient brains, the fact that poly(PR) is also found in SCA36, and the lack of a 
direct correlation of arginine rich DPRs with neurodegeneration call into question the 
contribution of these DPRs in disease pathogenesis. 
DPRs and TDP-43 pathology:  While the exact role of TDP-43 dysfunction in ALS and 
FTD pathogenesis remains elusive, TDP-43 pathology is a hallmark of the majority of ALS 
cases and common FTD subtypes, including c9ALS/FTD.  Previous studies have 
demonstrated that TDP-43 pathology correlates with neurodegeneration and clinical 
phenotypes (Davidson et al., 2016).  Although one study demonstrated that c9ALS/FTD-
associated DPRs can cause TDP-43 mislocalization in Drosophila (Solomon et al., 2018), 
previous work in mice suggest that poly(GA) (Zhang et al., 2016), poly(GR) (Zhang et al., 
2018) , and poly(PR) (Zhang et al., 2019) alone cannot promote the formation of TDP-43 
inclusions.  Additionally in this thesis, I demonstrate that the presence of either poly(GP) 
or poly(PR) alone is insufficient to cause TDP-43 pathology in SCA36.  Together these 
finding suggest that DPRs do not cause TDP-43 pathology. 
Insight from atypical C9orf72 cases:  A number of unique cases associated with the 
C9orf72 repeat expansion have been reported that provide unique insight into putative 
pathomechanisms.  One such case describes a patient who had abundant DPR pathology 
and RNA foci but no apparent TDP-43 pathology in a part of temporal lobe that had been 
surgically resected five year prior to disease onset (Vatsavayai et al., 2016).   Interestingly, 
at the time of autopsy, the patient had developed TDP-43 pathology.  This case 
demonstrated that DPR pathology was present in the CNS before onset of disease and 
preceded TDP-43 pathology.  Furthermore, it seems plausible that DPR pathology is 
present in early life.  Other neurodegenerative disease pathologies such as TDP-43, Tau, 
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or Aß pathology are dependent on some upstream dysfunction occurring prior to 
aggregation.  The aggregate prone nature of DPRs, specifically, poly(GA) suggests that 
production of these DPRs from C9orf72 RNA would be the only requirement for them to 
aggregate, thus it is likely that DPR pathology occurs in early life.  A second intriguing 
case reported a healthy individual who harbored only 70 G4C2 repeats but had robust DPR 
pathology and RNA foci throughout the CNS(McGoldrick et al., 2018).   The patient’s 
daughter presented with ALS and harbored ~1750 G4C2 repeats.  The authors argue that 
these findings do not negate the toxicity of DPRs but suggest that DPRs alone are 
insufficient to cause neurodegeneration. 
Individual vs mixed DPR populations:  To date, the majority of studies have focused on 
investigating mechanisms of toxicity associated with one DPR species at a time.  However, 
it is well established that more than one DPR inclusion can exist within the same cell.  
Therefore, it will be necessary to see how interactions among DPRs could modulate their 
toxicity.  A key finding from my thesis work is that dipeptide repeats are not 
homogenous throughout the peptide and may in fact form chimeric proteins 
consisting of more than one dipeptide repeat, e.g. GAGP.  In Chapter 2 I demonstrate 
that chimeric GAGP DPRs shift the solubility of poly(GP) from soluble to insoluble, and 
result in poly(GP) inclusions, similar to observed poly(GP) neuropathology in 
c9ALS/FTD.  Investigations into the toxicity of poly(GP) have only considered soluble 
poly(GP), however my findings suggest that chimeric species may modulate the toxicity 
of both poly(GA) or poly(GP).  The implications for chimeric DPRs are potentially more 
important in the case of GAGR chimeric DPRs.  Our finding of chimeric GAGP DPRs, 
supports the idea that other chimeric DPR species may exist, though this has not yet been 
experimentally verified.  Given the robust toxicity associated with poly(GR) it stands to 
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reason that changes in poly(GR) localization or solubility could modify GR associated 
toxicity. 
4.3 The argument for RNA-mediated toxicity in c9ALS/FTD 
Toxicity resulting from repeat containing RNA is a likely culprit in many microsatellite 
expansion disorders.  The archetypical example is that of myotonic dystrophy type 1.  
Characteristic of many microsatellite expansion disorders and inherent to arguments in 
favor of repeat toxicity is the formation of intranuclear RNA inclusions (RNA “foci”) (La 
Spada and Taylor, 2010).  In the initial report describing the C9orf72 mutation, RNA foci 
were reported (DeJesus-Hernandez et al., 2011) and a number of follow up studies have 
thus focused on understanding how toxic G4C2 containing RNA results in 
neurodegeneration.  The fundamental hypothesis is that repeat containing RNA sequester 
RNA-binding proteins, effectively resulting in their loss of function; however, to date, 
findings from various studies have been contradictory (Haeusler et al., 2016).  This may be 
due to the fact that while RNA foci are found in both affected and non-affected regions of 
the CNS (DeJesus-Hernandez et al., 2017), the toxicity of repeat containing RNAs has not 
been considered in the context of disease relevant cell types.  In Chapter 3, I provided 
preliminary data to show that including only those RNA-protein interactions that are 
plausible in a given cell type based on transcriptome-wide expression profiles, narrows 
down potential hits.  While I only cross-referenced interactors with iPS-MN RNA 
expression, a better approach would be to compare to the proteome of a given a cell type.  
Nonetheless, whether considering the transcriptome or the proteome to cross-reference to, 
identification of RNA-protein interactions is limited to the assay (e.g. protein array vs. 
MS2) and/or cell-type (e.g. HEK293T) used.  A better approach would be to identify RNA-
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protein interactions directly in iPS-derived motor neurons through the use of RNA tagging 
(e.g. MS2) or RNA targeting systems (e.g. Cas13a).  Additionally, the prevailing thought 
is that RNA toxicity is mediated through formation of RNA foci, however soluble repeat 
containing RNA species have not been considered.  I believe moving forward, studies 
should consider, for example, sequestered RNA binding proteins in nuclear (RNA foci) 
and cytoplasmic fractions (presumably soluble RNA species). 
Converging evidence suggests that dysfunction in RNA metabolism and processing plays 
a key role in ALS pathogenesis.  Mutations in a number of RNA-binding proteins have 
been linked to ALS including variants in TARDBP, FUS, and HNRNPA2B1.  Furthermore, 
I believe the role of RNA-mediated toxicity is further supported by data generated in this 
thesis as well as from previous reports in C9orf72 mouse models.  An intriguing finding 
from this study is that TDP-43 pathology, a hallmark of c9ALS/FTD, is absent in SCA36 
patients.  The highly similar hexanucleotide repeat sequences in these two disorders reside 
on different genes, and thus expression differences could contribute to the selective 
vulnerability of certain neuronal populations.  However, we have found that NOP56 
expression is higher than C9orf72 in all regions surveyed.  Additionally, NOP56 is essential 
for ribosomal biogenesis and thus it is likely expressed in the majority of neuronal and non-
neuronal populations.  In support of an RNA over DPR mode of toxicity are findings 
associated with AAV mouse models.  Expression of the c9ALS/FTD-associated expanded 
G4C2 repeat in mice results in TDP-43 pathology (Chew et al., 2019; Chew et al., 2015) 
while expression of DPRs alone are insufficient (Zhang et al., 2018; Zhang et al., 2016; 
Zhang et al., 2019), suggesting that TDP-43 dysfunction in c9ALS/FTD results from RNA-
mediated toxicity, from a combination of various DPRs, or from some combination of these 
mechanisms.  While the exact role of TDP-43 pathology in the pathogenesis of ALS 
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remains to be determined, the majority of cases exhibit this pathological hallmark and 
TDP-43 pathology is correlated with neurodegeneration.  Moving forward, an important 
question to shed light on in the field is why TDP-43 pathology occurs in ALS and FTD.  
4.4 Concluding Remarks 
In the conclusion of Jean Cruveilhier’s 1853 report of progressive muscular atrophy/ALS 
he poses the question “What is the cause of the atrophy of the anterior spinal nerve roots” 
(Cruveilhier, 1853; Drouin et al., 2016)?  Despite more than 100 years of efforts since to 
answer this question, we are only incrementally closer to understanding what molecular 
mechanism underlies degeneration of motor neurons.  In this thesis, I hoped to shed insight 
into the pathogenesis of ALS, and by extension FTD and SCA36, by comparing molecular 
mechanisms associated with genetic forms of these disorders.  I demonstrated that 
neuropathological hallmarks of the most common genetic form of ALS and FTD are also 
present in a seemingly disparate disorder, SCA36.  Intriguingly these neuropathological 
hallmarks, while composed of the same proteins, differ in their solubility and aggregation 
propensity in the human brain.  This comparative approach allowed me to demonstrate that 
the divergence in the observed pathology between these two disorders results from the 
production of chimeric dipeptide repeats in c9ALS/FTD.  The implications of chimeric 
DPRs in disease pathogenesis are far-reaching, as our current understanding associated 
with DPR pathology and toxicity is based on studies using single DPR species.  It remains 
to be seen if these chimeric DPRs modify (by either mitigating or exacerbating) the toxicity 
associated with DPRs.  Similarly, comparison of c9ALS/FTD and SCA36 repeat RNA-
protein interactions yielded insight into shared and unique repeat RNA-protein 
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interactions.  Ultimately, I hope that this thesis proves the utility of a comprehensive and 
comparative approach to elucidating relevant mechanisms in neurological disorders.  
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CHAPTER 5. METHODS AND MATERIALS 
Lysate preparation 
Adherent cells (HEK293T, fibroblast, iPS, iPS-motor neurons) were directly lysed in ice-
cold co-IP buffer (50mM Tris–HCl, pH 7.4, 300mM NaCl, 1% Triton X-100, 5mM EDTA, 
2% SDS) with 1x HALT protease and phosphatase inhibitors (Pierce).  Lysates were 
sonicated at 25% amplitude for 3 cycles of 5 seconds on/5 seconds off.  Cells in suspension 
(lymphoblastoid cell lines, 3D forebrain organoids) were first pelleted by centrifugation 
for 5 minutes at 300xg and subsequently lysed as was done for adherent cells. 
Immunoblotting 
For western blots, protein lysates were prepared in 4x loading buffer, heat-denatured at 
70oC for 15 minutes.  Samples were normalized to equal amounts and resolved on 10% 
Bis-Tris gels (Thermo Fisher), transferred to 0.44 µm PVDF membranes, and blocked in 
Licor Odyssey blocking buffer (Licor) for 1 hour.  The membrane was incubated overnight 
at 4oC with primary antibodies diluted in blocking buffer.  Secondary antibodies were 
diluted in blocking buffer and applied to membrane for 1 hour at R.T.  Primary antibodies 
used in immunoblotting experiments included anti-pTDP43 (1:3000, Cosmo Bio), anti-
TDP (1:1000, Protein Tech), anti-FLAG (1:1000, Sigma), anti-HA (1:1000, Cell 
Signaling), and anti-cMyc (1:1000, Roche)   For dot blots, 1.5 µL of urea soluble protein 
fractions were applied to a pre-wetted PVDF membrane and allowed to air dry for ~1.5 
hours at R.T.  The membrane was blocked in 5% non-fat dry milk for 1 hour and 
subsequently probed with purified anti-poly(GP) (Rb9258) overnight at 4oC. 
Sequential biochemical fractionation 
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Tissue lysates were fractionated according to previous published protocols(Neumann et al., 
2006).  In brief, ~200mg tissue was homogenized in low salt buffer (10mM Tris, 5mM 
EDTA, 1mM DTT, 10% sucrose, 1x HALT protease/phosphatase inhibitor).  Lysates were 
pelleted at 25,000g for 30 min.  Supernatants were collected as the “low salt” fraction.  The 
resulting pellet was solubilized in Triton-X buffer (low salt buffer + 1% triton X-100 + 
0.5M NaCl).  Lysates were subsequently pelleted at 180,000g for 30 min.  Supernatants 
were collected as the “Triton-X” fraction.  The resulting pellet was solubilized in Triton-X 
buffer + 30% sucrose.  Lysates were subsequently pelleted at 180,000g for 30 min.  
Supernatants from this fraction were not used for analysis.  The resulting pellet was 
solubilized in Sarkosyl buffer (low salt buffer + 1% sarkosyl + 0.5M NaCl).  Lysates were 
subsequently pelleted at 180,000g for 30 min.   Supernatants were collected as the “Sark” 
fraction.  The resulting insoluble pellet was resolubilized in 8M urea. 
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde for 10 minutes at R.T.  Cells were washed 3x 
with 1x PBS and permeabilized for 10 min in 1x PBST (0.1% Triton-X).  Cells were then 
blocked in 5% normal donkey serum (Jackson Labs) for 1 hour at R.T.  Cells were 
incubated with primary antibodies (Table S3) in 5% normal donkey serum overnight at 
4oC.  The next day cells were washed 3x in PBS and incubated with secondary antibodies 
(Alexa Fluor, 1:1500) for 1 hour at R.T.   
Meso-Scale Discovery (MSD) immunoassay 
The expression of poly(GP) in brain, organoid or cell lysates, as well as CSF, was measured 
blinded using a previously described sandwich immunoassay that utilizes MSD 
electrochemiluminescence detection technology, and an affinity purified rabbit polyclonal 
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poly(GP) antibody (Rb9259) for both the capture and the detection antibody(Gendron et 
al., 2017; Gendron et al., 2015). In brief, lysates were diluted in Tris-buffered saline (TBS) 
such that all samples of a given type were made up to the same concentration and an equal 
amount of protein for samples was tested in duplicate wells. CSF samples were tested in 
duplicate wells using 90 µl per well. Response values corresponding to the intensity of 
emitted light upon electrochemical stimulation of the assay plate using the MSD 
QUICKPLEX SQ120 were acquired. These response values were background corrected by 
subtracting response values from corresponding negative controls (e.g., lysates from 
tissues or cells lacking a repeat expansion). 
Animals 
Wildtype pregnant mice (E13) maintained on a C57BL/6 background and C57BL/6 wild 
type (WT) mice were obtained from Charles River. The animal protocol was approved by 
the Institutional Animal Care and Use Committees of Emory University and complied with 
the Guide for the Care and Use of Laboratory Animals. 
Intracerebroventricular injection (ICV) of AAV in newborn pups: 
Neonates at postnatal day 0 after birth are collected from the cage and cryoanesthesized at 
0°C for ca.5 min until movement stops before injection. A solution of recombinant AAV 
virus diluted in sterile saline containing the opaque tracer Evans blue (0.1%; to visualize 
the borders of the lateral ventricle after injection) is injected stereotactically into the 
ventricles using a 10 μL Nanofil syringe with a 33 gauge needle. The injection site is 
located 1 mm lateral to the sagittal suture, halfway between lambda and bregma. The needle 
was held perpendicular to the skull surface during insertion into the lateral ventricle. Once 
the needle was in place, 1-2 μL of viral solution were injected slowly (33 nl/sec) with a 
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MicroSyringe Pump Controller into the lateral ventricle. One minute after the injection is 
complete, the needle was withdrawn slowly and the injection procedure was repeated for 
the other ventricle. Post injection the pups were placed on another polystyrene weight boat 
with cage bedding on a warming pad (Deltaphase Isothermal Pad) until they regained 
normal color and resumed movement. Post recovery, the whole litter was returned to the 
mother together.   
Tissue Processing 
Mice were transcardially perfused with ice cold PBS followed by cold 4% 
Paraformaldehyde (Sigma). The brains were post fixed overnight in PFA followed by 
cryoprotection in 30% sucrose for ~ 48 hours ( brain sank to the bottom) 
Immunohistochemistry 
Paraffin embedded sections (5µm or 8µm) were deparaffinized in Histo-clear (National 
Diagnostics) and rehydrated in ethanol.  Antigen retrieval was performed in ddH2O by 
steam heat for 30 minutes.  Endogenous peroxidase activity was quenched using hydrogen 
peroxide and washed 3x in TBS-T.  Tissue sections were blocked using serum-free protein 
block (Dako) for 1 hour.  Primary antibodies were applied for 45 minutes at R.T. and 
washed 3x in TBS-T.  HRP-conjugated secondaries (Dako) were applied for 30 minutes at 
R.T.  Peroxidase labeling was visualized with 3,3’-diaminobenzidine (DAB).  Sections 
were subsequently counterstained with Gill’s hematoxylin and blued in Scott’s tap water 
substitute.  
Digital Spatial Profiling 
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An automated setup capable of imaging and sample collection was developed by modifying 
a standard microscope. For protein detection, a multiplexed cocktail of primary antibodies, 
each with a unique, UV photocleavable indexing oligo, and/or 1-3 fluorescent markers 
(antibodies and/or DNA dyes) was applied to a slide-mounted FFPE tissue section.  
The tissue slide was placed on the stage of an inverted microscope. A custom gasket was 
then clamped onto the slide, allowing the tissue to be submerged in 1.5 mL of buffer 
solution.  
The microcapillary tip is connected to a syringe pump primed with buffer solution, 
allowing for accurate aspiration of small volumes (<2.5 µL). Under the microscope, wide 
field fluorescence imaging was performed with epi-illumination from visible LED light 
engine. The tissue area of interest was then located using fluorescence imaging. 20x image 
corresponds to 650µm x 650µm of tissue area with a CMOS camera. The 20x images were 
stitched together to yield a high-resolution image of the tissue area of interest. The regions 
of interest (ROIs) were then selected based on the fluorescence information and 
sequentially processed by the microscope automation.  
The steps performed for each ROI by the microscope automation were as follows: First, 
the microcapillary tip was washed by dispensing clean buffer out the capillary and into a 
wash station. Next, the tissue slide was bulk washed by exchanging the buffer solution on 
the slide via the inlet and outlet wash ports on the gasket clamp. The microcapillary tip was 
then moved into position directly over the ROI with a distance of 50 µm from the tissue. 
The local region of tissue around the ROI was washed by dispensing 100 µL of buffer 
solution from the microcapillary. Then, the area of tissue within the ROI was selectively 
illuminated with UV light to release the indexing oligos. UV LED light was collimated to 
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be reflected from the DMD surface into the microscope objective and focused at the sample 
tissue.  Each micro mirror unit in the DMD corresponds to ~1µm2 area of sample and 
reflects the UV light in controlled pattern based on the ROI selection in the image. 
Following each UV illumination cycle, the eluent was collected from the local region via 
microcapillary aspiration and transferred to an individual well of a microtiter plate or strip 
tubes. Once all ROIs were processed, indexing oligos were hybridized to NanoString 
optical barcodes for ex situ digital counting and subsequently analyzed with an nCounter® 
Analysis System.  
Genomic DNA (gDNA) extraction and repeat-primed PCR (RP-PCR) 
Genomic DNA was extracted from patient cerebellum using the Puragene Kit (Qiagen) as 
per the manufacturer’s protocol.  RP-PCR was performed as previously 
described(DeJesus-Hernandez et al., 2011) with slight modifications.  PCR reactions were 
performed in 50uL total reaction volumes containing 100ng sample gDNA, 1x SuperFi 
Buffer (Invitrogen), 0.2mM dNTPs (Invitrogen), 0.5µM primer mix, 1x SuperFi GC 
enhancer, and 0.02 U/µL Platinum SuperFi DNA polymerase (Invitrogen)  PCR cycling 
conditions were as follows: 95oC for 2 minutes, 34 cycles of 98oC for 10 seconds, 64.7oC 
for 10 seconds, 72oC for 40 seconds, followed by a final elongation step at 72oC for 5 
minutes.  
RNA extraction and quantitative reverse transcription with PCR (RT-PCR) 
RNA was extracted using the Quick RNA kit (Zymo Research) with a combined on-column 
DNase I digestion step.  Adherent cells were directly lysed in the culture dish and RNA 
extraction proceeded per the manufacture’s protocol.  For RNA extraction from post-
mortem tissue, ~30mg of tissue was homogenized in lysis buffer using a bullet blender 
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tissue homogenizer (Next Advance).  RNA lysates were cleared by spinning samples at 
10,000g for 1 minute.  Cleared lysates were used for RNA extraction as per the 
manufacture’s protocol.  cDNA was obtained via RT-PCR using the High Capacity cDNA 
Reverse Transcription Kit (Thermo). 
To quantify relative mRNA expression for C9orf72 and NOP56, qPCR was peformed for 
each sample using Taqman gene expression assays (Thermo) on a Quantstudio 6 Flex 
system (Applied Biosystems).  For qPCR analysis of tissue samples, the following FAM 
labelled Taqman assays were used Hs00376619 (C9orf72) and Hs0197340 (NOP56).  
Relative tissue RNA expression was normalized to the geometric mean Ct values of 
UBE2D2 and Cyc1, endogenous reference transcripts previously demonstrated to be stable 
across human brain regions in neurodegenerative diseases(Rydbirk et al., 2016).  For qPCR 
analysis of ASO treated fibroblast a custom FAM labelled Taqman assay spanning the exon 
1-exon 2 splice junction of NOP56 was used (AI89MBZ).  Relative RNA expression was 
normalized to RPLP0. 
RNA sequencing 
For RNA sequencing of iPS-derived neurons, strand specific poly-A selected libraries were 
constructed (Kapa) and sequenced on an Illumina NextSeq500 sequencer with 30 million 
reads per replicate (2 x 150bp). For RNA sequencing of cerebellar cortex samples, poly-A 
selected libraries were constructed (NEB) and sequenced on an Illumina Novaseq 
sequencer with 80 million pair-end reads per replicate (2 x 150bp). Transcript abundances 
were quantified as transcripts per million (TPMs) and then collapsed to gene abundances 
using Salmon. Alternative splicing events were identified based on RNA-seq coverage 
using rMATS and PSI values of differential splicing were obtained. Stringent cutoffs for 
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differential splicing events were set to FDR < 0.05, Inclusion level difference > -0.1, and 
min counts ≥ 20. Splicing scatter plots were generated using R-studio and Sashimi plots 
were generated for the visualization of splicing events. Pathway enrichment of genes in 
RNAseq were performed on gene ontology (GO) terms using Gorilla.  
Generation of induced pluripotent stem cells (iPS) 
iPSCs were generated as previously described(Holler et al., 2016) using the Cytotune 2.0 
Kit (Life Technologies) per the manufacturer’s protocol.  In brief, early passage fibroblast 
(<P10) were grown to \ in fibroblast medium consisting of 10% ES-qualified FBS (Life 
Technologies), 0.1 mM NEAA, 55µM β-mercaptoethanol, high glucose DMEM with 
Glutamax (Life Technologies).  On Day 0, fibroblasts were transduced with Sendai virus 
encoding KOS, hc-Myc, hKlf4, each at a MOI of 5.  Cells were fed with fibroblast medium 
every other day for one week.  On day 7, cells were passaged onto vitronectin (Life 
Technologies) coated dishes at a density of 250,000 to 500,000 cells/well.  Beginning on 
day 8, cells were fed every day in Essential 8 medium (Life Technologies).  iPS colonies 
were manually picked and transferred to a dish coated with either vitronectin or Matrigel 
(BD).  iPSCs were maintained on Matrigel coated dishes and mTesR1 medium (Stem Cell 
Technologies).  iPSCs were passaged every 5-7 days using ReLeSR. 
Generation of 3D forebrain organoid 
iPSCs colonies were detached from Matrigel coated plates with collagenase (1mg/ml; 
Invitrogen) treatment for 1hr and suspended in EB medium, comprising of FGF-2-free 
hESC medium supplemented with Dorsomorphin (2μM; Tocris) and A-83 (2μM; Tocris), 
in non-treated polystyrene plates for 4 days with a daily medium change. On days 5-6, half 
of the medium was replaced with induction medium consisting of DMEM:F12, N2 
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Supplement (1X; Invitrogen), 10μg/ml Heparin (Sigma), NEAA (1X), Glutamax (1X), 
WNT-3A (4 ng/ml; R&D Systems), CHIR99021 (1μM; Cellagentech), and SB-431542 
(1μM; Cellagentech). On day 7, organoids were embedded in Matrigel (Corning) and 
continued to grow in induction medium for 6 more days. On day 14, embedded organoids 
were mechanically dissociated from Matrigel by pipetting up and down onto the plate with 
a 5ml pipette tip. Typically, 10 – 20 organoids were transferred to each well of a 12-well 
spinning bioreactor (SpinΩ)(Qian et al., 2016) containing differentiation medium, 
consisting of DMEM:F12, N2 (1X), B27 (1X;  Invitrogen), 2-Mercaptoenthanol (100µM), 
NEAA (1X), Insulin (2.5μg/ml; Sigma). At day 71, differentiation medium was exchanged 
with maturation medium, consisting of Neurobasal (Invitrogen), B27 (1X), 2-
Mercaptoenthanol (100 µM), 0.2mM Ascorbic Acid (Sigma), 20 ng/ml BDNF (Peprotech), 
20ng/ml GDNF (Peprotech), 1 ng/ml TFGβ (Peprotech), and 0.5 mM cAMP (Sigma). 
Media was changed every other day until day 105 when organoids were collected for 
protein lysates. 
iPS-motor neuron differentiation 
Prior to differentiation, iPS colonies were treated with 10µM ROCK inhibitor, Y-27632 
(Stem Cell Technologies), for ~1 hour.  iPSCs were treated with Accutase (Stem Cell 
Technologies) for ~8 min to obtain a single cell suspension.  Cells were spun out of 
Accutase and resuspended in N2B27 differentiation medium (1:1 Advanced DMEM-
F12/Neurobasal, 1x N2, 1x B27, 0.2% Penstrep, 1x Glutamax, 110µM β-mercaptoethanol) 
and seeded in 10cm Ultra-Low Attachment dishes (Corning) in order to form embryoid 
bodies.  Cells were maintained as embryoid bodies throughout the differentiation and were 
fed every 2 days.  For the first 2 days, the differentiation medium contained 3µM 
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CHIR99021 (Stem Cell Technologies), 10µM SB431542 (Stemgent), 5µM DMH1 
(Tocris), and 10µM Y-27632 (Tocris).  Starting on day 2, 1µM Retinoic Acid (Sigma) and 
500nM Smoothened Agonist (Millipore) were added to the medium and Y-27632 was 
removed.  On Day 8, CHIR99021 was removed from the medium.  On Day 8, SB and 
DMH1 were removed from the medium.  On day 15, 10µM DAPT (Tocris) was added.  
10ng/mL BDNF (Peprotech) and 10ng/mL GDNF (Peprotech) were added to the media on 
day 16.  On day 20, embryoid bodies were disassociated to single cells using papain/DNase 
(Worhtington Bio) and plated on polyornithine/laminin (3.3 µg/mL) coated glass 
coverslips or cell culture plates.  Disassociated neurons were maintained in N2B27 
maintainence medium (Neurobasal, 1x N2, 1x B27 plus, 0.2% Penstrep, 1x Glutamax, 
110µM β-mercaptoethanol) supplemented with 10ng/mL BDNF and 10ng/mL GDNF.  
Neurons were refed every 2-3 days. 
Statistics 
All data is presented as mean ± standard error of the mean (SEM).  Data was analyzed 
using unpaired, two-tailed, Student’s t-test, Kruskal-Wallis analysis of variance, one-way 
ANOVA followed by Dunn’s post hoc or Dunnett’s post hoc analysis, or two-way ANOVA 
followed by Sidak’s post hoc analysis (GraphPad Prism 7).  Data obtained from poly(GP) 
immunoassays were considered to be non-normally distributed.  Data from qPCR was 
assumed to be normally distributed.  Statistical analysis of qPCR data was performed on 





Table 5.1: Antibodies used in this study 
 
  
Antibody Dilution Experiment Form Company Catalog # Notes 
poly(GP) 1:5000 IHC Sera Millipore ABN455 
 
poly(GP) 1:1000 Dotblot AP Petrucelli Lab Rb9258 
 
poly(PR) 1:50 IHC AP Petrucelli Lab Rb8736 See Ref [31] 
pTDP-43 1:3000 IB/IHC Sera Cosmo Bio TIP-PTD-P02 1:1 glycerol 
TDP-43 1:1000 IB/IHC AP Protein Tech 10782-2  
p62 1:250 IHC AP BD Biosciences 610832  
FLAG 1:1000 IB/IF AP Sigma F1804 1:1 glycerol 
cMyc 1:1000 IB/IF AP Roche 11667149001 1:1 glycerol 
HA 1:1000 IB/IF AP CST 3724  
GFP 1:3000 IB/IF AP Clonetech 632381 1:1 glycerol 
GAPDH 1:3000 IB AP CST 5174  
Islet1 1:250 IF Sera DSHB 40.2D6  
Tuj1 1:1500 IF AP Covance MRB-435P  
Oct4 1:400 IF AP CST 2840  
SSEA3/4 1:500 IF AP CST 4755  
Nanog 1:200 IF AP R&D Systems AF1997 1:1 glycerol 
Sox2 1:200 IF AP Thermo PA1-16968  
Tra1-60 1:150 IF AP Millipore MAB4360  
Tra1-81 1:150 IF AP Millipore MAB4381  
AP=affinity purified, IB=immunoblot, IHC=immunohistochemistry, IF=immunofluorescence 
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